United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 20202021
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                              to                              
Commission File Number: 000-23661
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware38-3317208
(State or other jurisdiction of

incorporation or organization)
(I.R.S. Employer

Identification No.)
411 Hackensack Avenue, Suite 501,30142 S. Wixom Road, Wixom, MichiganHackensack,New Jersey0760148393
(Address of principal executive offices)(Zip Code)
(248) (248) 960-9009
(Registrant’s telephone number, including area code)
(

Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes    ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  ☒  Yes    ☐  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☒☐
Non-accelerated filer☐☒Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐  Yes  ☒
  No
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:Trading SymbolName of each exchange on which registered:
Common Stock, par value $0.0001RMTINasdaq Global Market
The number of shares of common stock outstanding as of August 7, 202013, 2021 was 70,297,814.
93,888,881.



Rockwell Medical, Inc. and Subsidiaries
Index to Form 10-Q
Page
Page
Part I — Financial Information (unaudited)
Item 1 - Financial Statements
Condensed Consolidated Balance Sheets as of June 30, 20202021 and December 31, 20192020
3
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 20202021 and 20192020
4
Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months EndedJune 30, 20202021 and 20192020
5
Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Six Months Ended June 30, 20202021 and 20192020
6
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 20202021 and 20192020
8
7
Notes to Condensed Consolidated Financial Statements
10
8
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
27
Item 3 - Quantitative and Qualitative Disclosures about Market Risk
34
36
Item 4 - Controls and Procedures
34
36
Item 1 -    Legal Proceedings
35
37
Item 1A - Risk Factors
36
37
Item 6 -    Exhibits
41
44
43
45
2

PART I – FINANCIAL INFORMATION
Item 1.  Financial Statements
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
June 30,
2020		 December 31,
2019		June 30,
2021		December 31,
2020
(Unaudited)  (Unaudited)
ASSETS   ASSETS
Cash and Cash Equivalents$26,697,063
 $11,794,526
Cash and Cash Equivalents$32,378 $48,682 
Investments Available-for-Sale13,258,197
 14,250,176
Investments Available-for-Sale8,574 9,997 
Accounts Receivable, net3,565,292
 4,202,725
Accounts Receivable, net5,357 4,171 
Inventory, net4,557,177
 3,646,906
Inventory, net4,677 3,913 
Prepaid and Other Current Assets3,458,104
 2,979,504
Prepaid and Other Current Assets1,413 2,706 
Total Current Assets51,535,833
 36,873,837
Total Current Assets52,399 69,469 
Property and Equipment, net2,306,462
 2,433,405
Property and Equipment, net2,529 2,642 
Inventory, Non-Current821,000
 441,000
Inventory, Non-Current1,122 1,176 
Right of Use Assets, net2,440,115
 3,212,530
Right of Use Assets, net6,085 2,911 
Goodwill920,745
 920,745
Goodwill921 921 
Other Non-Current Assets560,588
 434,935
Other Non-Current Assets628 629 
Total Assets$58,584,743
 $44,316,452
Total Assets$63,684 $77,748 
LIABILITIES AND STOCKHOLDERS’ EQUITY   LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable$3,313,240
 $3,018,424
Accounts Payable$4,932 $4,155 
Accrued Liabilities4,437,080
 4,517,732
Accrued Liabilities3,993 5,013 
Settlement Payable—
 104,000
Lease Liability - Current1,342,228
 1,493,394
Lease Liability - Current1,674 1,167 
Deferred License Revenue - Current2,174,626
 2,233,640
Deferred License Revenue - Current2,166 2,175 
Insurance Financing Note Payable—
 763,422
Term Loan - Net of Issuance CostsTerm Loan - Net of Issuance Costs21,133 0 
Customer Deposits38,273
 55,100
Customer Deposits140 152 
Other Current Liability - Related Party189,600
 187,849
Other Current Liability - Related Party0 131 
Total Current Liabilities11,495,047
 12,373,561
Total Current Liabilities34,038 12,793 
   
Lease Liability - Long-Term1,204,210
 1,780,626
Lease Liability - Long-Term4,506 1,821 
Term Loan, Net of Issuance Costs20,764,213
 —
Term Loan, Net of Issuance Costs0 20,949 
Deferred License Revenue - Long-Term8,909,703
 9,842,762
Deferred License Revenue - Long-Term6,937 8,015 
Total Liabilities42,373,173
 23,996,949
Total Liabilities45,481 43,578 
   
Commitments and Contingencies (See Note 14)


 


Commitments and Contingencies (See Note 14)00
   
Stockholders’ Equity:   Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019—
 —
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 70,156,922 and 65,378,890 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively7,017
 6,538
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2021 and December 31, 2020Preferred Stock, $0.0001 par value, 2,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2021 and December 31, 20200 0 
Common Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectivelyCommon Stock, $0.0001 par value; 170,000,000 shares authorized; 93,811,381 and 93,573,165 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively9 9 
Additional Paid-in Capital337,551,385
 326,777,250
Additional Paid-in Capital371,700 371,510 
Accumulated Deficit(321,392,548) (306,516,265)Accumulated Deficit(353,558)(337,406)
Accumulated Other Comprehensive Income45,716
 51,980
Accumulated Other Comprehensive Income52 57 
Total Stockholders’ Equity16,211,570
 20,319,503
Total Stockholders’ Equity18,203 34,170 
Total Liabilities and Stockholders’ Equity$58,584,743
 $44,316,452
Total Liabilities and Stockholders’ Equity$63,684 $77,748 
The accompanying notes are an integral part of the condensed consolidated financial statements.
3

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)(Dollars in Thousands, Except Per Share Amounts)
Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019Three Months Ended June 30, 2021Three Months Ended June 30, 2020Six Months Ended June 30, 2021Six Months Ended June 30, 2020
       
Net Sales$15,895,971
 $14,845,788
 $31,752,510
 $30,405,227
Net Sales$15,137 $15,896 $30,611 $31,753 
Cost of Sales15,015,404
 14,112,639
 29,759,017
 28,661,686
Cost of Sales15,399 15,015 30,471 29,759 
Gross Profit880,567
 733,149

1,993,493

1,743,541
Gross Profit(262)881 140 1,994 
Research and Product DevelopmentResearch and Product Development2,416 1,616 4,224 3,438 
Selling and Marketing1,996,595
 2,218,997
 4,069,393
 5,321,375
Selling and Marketing1,468 1,997 3,319 4,069 
General and Administrative2,871,013
 5,496,670
 8,144,445
 11,717,169
General and Administrative3,677 2,871 7,602 8,145 
Settlement Expense—
 430,000
 —
 430,000
Research and Product Development1,616,393
 2,958,276
 3,437,881
 3,455,552
Operating Loss(5,603,434) (10,370,794) (13,658,226) (19,180,555)Operating Loss(7,823)(5,603)(15,005)(13,658)
       
Other Income (Expense)       
Realized Gain on Investments2,065
 4,135
 3,994
 18,023
Other (Expense) IncomeOther (Expense) Income
Realized (Loss) Gain on InvestmentsRealized (Loss) Gain on Investments(1)2 (1)4 
Warrant Modification Expense(837,322) —
 (837,322) —
Warrant Modification Expense0 (837)0 (837)
Interest Expense(520,604) —
 (622,556) —
Interest Expense(583)(521)(1,164)(623)
Interest Income66,750
 74,476
 237,827
 192,002
Interest Income7 67 18 238 
Total Other Income(1,289,111) 78,611
 (1,218,057) 210,025
Total Other ExpenseTotal Other Expense(577)(1,289)(1,147)(1,218)
       
Net Loss$(6,892,545) $(10,292,183) $(14,876,283) $(18,970,530)Net Loss$(8,400)$(6,892)$(16,152)$(14,876)
       
Basic and Diluted Net Loss per Share$(0.10) $(0.18) $(0.22) $(0.33)Basic and Diluted Net Loss per Share$(0.09)$(0.10)$(0.17)$(0.22)
Basic and Diluted Weighted Average Shares Outstanding69,428,574
 58,216,066
 68,473,407
 57,660,947
Basic and Diluted Weighted Average Shares Outstanding93,703,492 69,428,574 93,647,583 68,473,407 
The accompanying notes are an integral part of the condensed consolidated financial statements.
4

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)(Dollars in Thousands)
Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019Three Months Ended June 30, 2021Three Months Ended June 30, 2020Six Months Ended June 30, 2021Six Months Ended June 30, 2020
       
Net Loss$(6,892,545) $(10,292,183) $(14,876,283) $(18,970,530)Net Loss$(8,400)$(6,892)$(16,152)$(14,876)
Unrealized Loss on Available-for-Sale Debt Instrument Investments(5,701) 11,426
 (12,411) 4,265
Unrealized Loss on Available-for-Sale Debt Instrument Investments(1)(6)(8)(13)
Foreign Currency Translation Adjustments536
 236
 6,147
 144
Foreign Currency Translation Adjustments0 1 3 7 
Comprehensive Loss$(6,897,710) $(10,280,521) $(14,882,547) $(18,966,121)Comprehensive Loss$(8,401)$(6,897)$(16,157)$(14,882)
The accompanying notes are an integral part of the condensed consolidated financial statements.
5

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Dollars in Thousands)
COMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT		ACCUMULATED
OTHER
COMPREHENSIVE
INCOME		TOTAL
STOCKHOLDERS'
EQUITY
SHARESAMOUNT
Balance as of January 1, 202193,573,165 $9 $371,510 $(337,406)$57 $34,170 
Net Loss— — — (7,752)— (7,752)
Unrealized Loss on Available-for-Sale Investments— — — — (7)(7)
Foreign Currency Translation Adjustments— — — — 3 3 
Stock-based Compensation26,354 — (236)— — (236)
Balance as of March 31, 202193,599,519 $9 $371,274 $(345,158)$53 $26,178 
Net Loss— — — (8,400)— (8,400)
Unrealized Loss on Available-for-Sale Investments— — — — (1)(1)
Vesting of Restricted Stock Units Issued, net of taxes withheld211,862 — (7)— — (7)
Stock-based Compensation expense— — 433 — — 433 
Balance as of June 30, 202193,811,381 $9 $371,700 $(353,558)$52 $18,203 
For
    The accompanying notes are an integral part of the three and six months ended June 30, 2020condensed consolidated financial statements.

(Unaudited)ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
 COMMON STOCK ADDITIONAL PAID-IN CAPITAL 
ACCUMULATED
DEFICIT
 
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
 
TOTAL
STOCKHOLDERS'
EQUITY
SHARES AMOUNT 
Balance as of January 1, 202065,378,890
 $6,538
 $326,777,250
 $(306,516,265) $51,980
 $20,319,503
Net Loss—
 —
 —
 (7,983,738) —
 (7,983,738)
Unrealized Loss on Available-for-Sale Investments—
 —
 —
 —
 (6,710) (6,710)
Foreign Currency Translation Adjustments—
 —
 —
 —
 5,611
 5,611
Issuance of common stock, net of offering costs/Bought Deal3,670,212
 367
 8,003,590
 —
 —
 8,003,957
Issuance of Warrants related to Debt Financing—
 —
 500,736
 —
 —
 500,736
Stock-based Compensation—
 —
 934,846
 —
 —
 934,846
Balance as of March 31, 202069,049,102
 $6,905
 $336,216,422
 $(314,500,003) $50,881
 $21,774,205
Net Loss—
 —
 —
 (6,892,545) —
 (6,892,545)
Unrealized Loss on Available-for-Sale Investments—
 —
 —
 —
 (5,701) (5,701)
Foreign Currency Translation Adjustments—
 —
 —
 —
 536
 536
Issuance of common stock, net of offering costs/Public offering987,716
 99
 1,977,531
 —
 —
 1,977,630
Vesting of Restricted Stock Units Issued, net of taxes withheld120,104
 13
 (18,876) —
 —
 (18,863)
Warrant Modification Expense—
 —
 837,322
 —
 —
 837,322
Stock-based Compensation expense—
 —
 (1,461,014) —
 —
 (1,461,014)
Balance as of June 30, 202070,156,922
 $7,017
 $337,551,385
 $(321,392,548) $45,716
 $16,211,570
(Dollars in Thousands)

COMMON STOCKADDITIONAL PAID-IN CAPITALACCUMULATED
DEFICIT		ACCUMULATED
OTHER
COMPREHENSIVE
INCOME		TOTAL
STOCKHOLDERS'
EQUITY
SHARESAMOUNT
Balance as of January 1, 202065,378,890 $7 $326,777 $(306,516)$52 $20,320 
Net Loss— — — (7,984)— (7,984)
Unrealized Loss on Available-for-Sale Investments— — — — (7)(7)
Foreign Currency Translation Adjustments— — — — 6 6 
Issuance of common stock, net of offering costs/Bought Deal3,670,212 — 8,003 — — 8,003 
Issuance of Warrants related to Debt Financing— — 501 — — 501 
Stock-based Compensation— — 935 — — 935 
Balance as of March 31, 202069,049,102 $7 $336,216 $(314,500)$51 $21,774 
Net Loss— — — (6,892)— (6,892)
Unrealized Loss on Available-for-Sale Investments— — — — (6)(6)
Foreign Currency Translation Adjustments— — — — 1 1 
Issuance of common stock, net of offering costs/Public Offering987,716 — 1,978 — — 1,978 
Vesting of Restricted Stock Units Issued, net of taxes withheld120,104 — (19)— — (19)
Warrant Modification Expense— — 837 — — 837 
Stock-based Compensation— — (1,461)— — (1,461)
Balance as of June 30, 202070,156,922 $7 $337,551 $(321,392)$46 $16,212 
The accompanying notes are an integral part of the condensed consolidated financial statements.

6

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITYCASH FLOWS
(Dollars in Thousands)
For the three and six months ended June 30, 20192021 and 2020
(Unaudited)
 COMMON STOCK ADDITIONAL PAID-IN CAPITAL 
ACCUMULATED
DEFICIT
 
ACCUMULATED
OTHER
COMPREHENSIVE
INCOME
 
TOTAL
STOCKHOLDERS'
EQUITY
SHARES AMOUNT 
Balance as of January 1, 201957,034,154
 $5,703
 $299,596,257
 $(272,388,234) $63,148
 $27,276,874
Net Loss—
 —
 —
 (8,678,347) —
 (8,678,347)
Unrealized Loss on Available-for-Sale Investments—
 —
 —
 —
 (7,161) (7,161)
Foreign Currency Translation Adjustments—
 —
 —
 —
 (92) (92)
Exercise of Employee Stock Options, Net of Tax30,000
 3
 147,897
 —
 —
 147,900
Delivery of common stock underlying restricted stock units, net of tax64,173
 7
 (95,436) —
 —
 (95,429)
Stock-based Compensation—
 —
 1,517,302
 —
 —
 1,517,302
Balance as of March 31, 201957,128,327
 $5,713
 $301,166,020
 $(281,066,581) $55,895
 $20,161,047
Net Loss—
 —
 —
 (10,292,183) —
 (10,292,183)
Unrealized Gain on Available-for-Sale Investments—
 —
 —
 —
 11,426
 11,426
Foreign Currency Translation Adjustments—
 —
 —
 —
 236
 236
Issuance of common stock, net of offering costs/Public offering5,833,334
 583
 16,120,096
 —
 —
 16,120,679
Issuance of common stock, net of offering costs/At-the-market offering437,043
 44
 2,089,164
 —
 —
 2,089,208
Stock-based Compensation—
 —
 1,501,326
 —
 —
 1,501,326
Balance as of June 30, 201963,398,704
 $6,340
 $320,876,606
 $(291,358,764) $67,557
 $29,591,739
20212020
Cash Flows From Operating Activities:
Net Loss$(16,152)$(14,876)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization385 408 
Stock-based Compensation197 (526)
Warrant Modification Expense0 837 
Increase in Inventory Reserves89 12 
Amortization of Right of Use Asset857 748 
Amortization of Debt Financing Costs and Accretion of Debt Discount184 108 
Loss on Disposal of Assets8 6 
Realized Loss (Gain) on Sale of Investments Available-for-Sale1 (4)
Foreign Currency Translation Adjustment3 6 
Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable, net(1,186)637 
Increase in Inventory(799)(1,302)
Decrease (Increase) in Prepaid and Other Assets1,293 (608)
Increase in Accounts Payable777 295 
Decrease in Settlement Payable0 (104)
Decrease in Lease Liability(839)(703)
Decrease in Other Liabilities(1,163)(96)
Decrease in Deferred License Revenue(1,088)(992)
Changes in Assets and Liabilities(3,005)(2,873)
Cash Used In Operating Activities(17,433)(16,154)
Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale(13,765)(16,514)
Sale of Investments Available-for-Sale15,181 17,497 
Purchase of Equipment(281)(283)
Cash Provided By Investing Activities1,135 700 
Cash Flows From Financing Activities:
Proceeds from Term Loan0 22,500 
Debt Issuance Costs0 (1,343)
Payments on Short Term Note Payable0 (763)
Proceeds from the Issuance of Common Stock / Public Offering0 8,148 
Offering Costs from the Issuance of Common Stock / Public Offering0 (144)
Proceeds from the Issuance of Common Stock / At-the-Market Offering0 2,034 
Offering Costs from the Issuance of Common Stock / At-the-Market Offering0 (56)
Repurchase of Common Stock to Pay Employee Withholding Taxes(6)(19)
Cash (Used In) Provided By Financing Activities(6)30,357 
(Decrease) Increase in Cash and Cash Equivalents(16,304)14,903 
Cash and Cash Equivalents at Beginning of Period48,682 11,794 
Cash and Cash Equivalents at End of Period$32,378 $26,697 
Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest$982 $410 
Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale$(7)$(12)
Fair Value of Warrants issued related to Debt Financing$0 $501 
The accompanying notes are an integral part of the condensed consolidated financial statements.


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the six months ended June 30, 2020 and 2019
(Unaudited)
7
 2020 2019
Cash Flows From Operating Activities:   
Net Loss$(14,876,283) $(18,970,530)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:   
Depreciation and Amortization407,680
 380,372
Stock-based Compensation(526,168) 3,018,628
Warrant Modification Expense837,322
 —
Increase in Inventory Reserves12,000
 192,000
Amortization of Right of Use Asset748,160
 975,947
Amortization of Debt Financing Costs and Accretion of Debt Discount107,527
 —
Loss (Gain) on Disposal of Assets6,048
 (300)
Realized (Gain) on Sale of Investments Available-for-Sale(3,996) (18,023)
Foreign Currency Translation Adjustment6,147
 144
Changes in Assets and Liabilities:   
Decrease in Accounts Receivable, net637,432
 1,590,656
Decrease in Insurance Receivable—
 371,217
(Increase) Decrease in Inventory(1,302,270) 66,141
(Increase) Decrease in Prepaid and Other Assets(607,574) 125,750
Increase (Decrease) in Accounts Payable294,816
 (426,772)
Increase (Decrease) in Settlement Payable(104,000) 13,332
Decrease in Lease Liability(703,327) (977,636)
Decrease in Other Liabilities(95,728) (992,909)
Decrease in Deferred License Revenue(992,073) (1,126,434)
Changes in Assets and Liabilities(2,872,724) (1,356,655)
Cash Used In Operating Activities(16,154,287) (15,778,417)
Cash Flows From Investing Activities:   
Purchase of Investments Available-for-Sale(16,513,592) (21,774,410)
Sale of Investments Available-for-Sale17,497,153
 18,798,678
Purchase of Equipment(283,462) (305,030)
Purchase of Research and Development Licenses (Related Party)—
 (500,000)
Cash Provided By (Used In) Investing Activities700,099
 (3,780,762)
Cash Flows From Financing Activities:   
Proceeds from Term Loan22,500,000
 —
Debt Issuance Costs(1,342,578) —
Payments on Short Term Note Payable(763,421) —
Proceeds from the Issuance of Common Stock / Public Offering8,147,871
 17,500,002
Offering Costs from the Issuance of Common Stock / Public Offering(143,914) (1,379,323)
Proceeds from the Issuance of Common Stock / At-the Market Offering2,034,073
 2,296,235
Offering Costs from the Issuance of Common Stock / At-the Market Offering(56,443) (207,027)

Proceeds from the Exercise of Employee Stock Options—
 147,900
Repurchase of Common Stock to Pay Employee Withholding Taxes(18,863) (95,429)
Cash Provided By Financing Activities30,356,725
 18,262,358
    
Increase (Decrease) In Cash and Cash Equivalents14,902,537
 (1,296,821)
Cash and cash equivalents At Beginning Of Period11,794,526
 22,713,980
Cash and cash equivalents At End Of Period$26,697,063
 $21,417,159
    
Supplemental Disclosure of Cash Flow Information:   
Cash Paid for Interest$409,931
 $—
Supplemental Disclosure of Noncash Investing and Financing Activities:   
Change in Unrealized Loss on Marketable Securities Available-for-Sale$(12,411) $4,265
Insurance Financing Note Payable$—
 $1,908,554
Fair Value of Warrants issued related to Debt Financing$500,736
 $—
The accompanying notes are an integral part of the condensed consolidated financial statements.

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)


1.  Description of Business
    
Rockwell Medical, Inc. and subsidiaries (collectively, “we”, “our”, “us”,("Rockwell Medical," "Rockwell" or the “Company”"Company"), is a commercial-stage, biopharmaceutical company dedicated to improving outcomes for patients withdeveloping and commercializing our next-generation parenteral iron deficiency and iron-deficiency anemia, with an initial focus on patients with end-stage kidney disease (ESKD) and on dialysis. The Company is focused on developing its proprietarytechnology platform, ferric pyrophosphate citrate (“FPC”) therapeutic platform. The, which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first producttwo products developed from this platform is Triferic, the first-FDA approved productour FPC platform. We are marketing both products to kidney dialysis centers for the replacement of iron and maintenance of hemoglobin in adult hemodialysis patients. We initiated commercial sales of Triferic Dialysate, during the second quarter of 2019 and received approval by the U.S. Food and Drug Administration ("FDA") for the intravenous formulation of Triferic, Triferic AVNU, on March 27, 2020. We plantheir patients receiving dialysis. In 2021, we intend to leverage our experience with Triferic to developadvance our FPC platform strategy outside of dialysis by starting a Phase II trial for iron deficiency andthe treatment of iron deficiency anemia in other disease states. patients outside of dialysis, who are receiving long-term and or chronic intravenous medications for various therapeutic needs in the home infusion setting. In our R&D pipeline, we are also exploring FPC’s impact in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.

We are also a manufacturerthe second largest supplier of hemodialysis concentrates for dialysis providers and distributors in the United States generating approximately $60 million in annual revenue. The Company's reputation for excellent service, quality, and abroad. We supply the domestic marketreliability is based on over 25 years of service to kidney dialysis centers. Our approximately 300 dedicated employees, as well as a management team with dialysis concentratesexperience in manufacturing, logistics, pharmaceutical development and we also supply dialysis concentratescommercialization gives us a solid foundation upon which to distributors serving a number of foreign countries, primarily in the Americas and the Pacific Rim.grow.
Our mission is to transform anemia management in a wide variety of disease states across the globe, while improving patients’ lives. Accordingly, we are building the foundation to become a leading medical and commercial organization in the field of iron deficiency.
Triferic® is a registered trademark of Rockwell Medical, Inc.
2.  Liquidity and Capital Resources
Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, 2020, the Company2021, Rockwell had approximately $26.7$41.0 million of cash, and cash equivalents $13.3 million ofand investments available-for-sale, and working capital of $40.0 million and an accumulated deficit of $321.4$18.4 million. Net cash used in operating activities for the six months ended June 30, 20202021 was approximately $16.2$17.4 million. Management evaluated

The Company is subject to certain covenants and cure provisions under its Loan Agreement with Innovatus. As of the Company’s abilitydate of this report, the Company is in compliance with all covenants. As a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to continue as going concern for at leastsatisfy such covenants over the next 12 months from the filing of this report. Basedmonths. However, based on the currently available working capital, capital raise and debt financing described below, management believesforegoing, the Company currently has sufficient funds to meet its operating requirements for at leastclassified amounts payable under the next twelve months from the date of the filing of this report.
In February 2020,Loan Agreement as a current liability. If and when the Company sold 3,670,212 sharesreaches an agreement with Innovatus to avoid an event of its common stockdefault, the amounts payable under the Loan Agreement will be reclassified. The financial statements for proceeds of $8.0 million, net of issuance costs. On March 16, 2020,June 30, 2021, have been prepared with the assumption that the Company closed a debt financing transactionwill be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. If the Company is unable to comply with net proceeds at closing of approximately $21.2 million, net of fees and expensesthe covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance (See Note 15 for further detail).
During the six months ended June 30, 2020, the Company sold 987,716 shares of its common stock as part of its sales agreement with Cantor Fitzgerald & Co. for proceeds of $2.0 million, net of issuance costs. Approximately $32.6 million remains available for sale under this facility. See Note 10 for further detail.

The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term businessstrategic plan, including the continued commercialization of Triferic Dialysate(dialysate) and Triferic AVNU executing plans for enhancing its medical capabilities,in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and developing Triferic for progressing our pipeline development program of new therapeutic indications.indications for its FPC platform. If the Company is unable to generate sufficient revenue from sales of its existing long-term business plan,commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

8

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The COVID-19 pandemic and resulting domestic and global disruptions have adversely affected ourRockwell's business and operations, including, but not limited to, our sales and marketing efforts, and our research and development activities, and the operations of third parties upon whom we rely. As noted above, we intend to initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch.Company relies. Quarantines, shelter-in-place, executive and similar government orders and the recent surge in infections domestically may continue to negatively impact ourRockwell's sales and marketing activities, particularly if ourits sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending onThe Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the severity of the impact on our salesrecent surge in infections internationally, ongoing international travel restrictions and marketing efforts, the timing of our commercial launch of Triferic AVNU could be adjusted into the first quarter of 2021.quarantines or shelter-in-place orders.

The COVID-19 pandemic, the domestic and international surge in infections and resulting global disruptions have caused significant volatility in financial and credit markets. We haveRockwell has utilized a range of financing methods to fund ourits operations in the past; however, current conditions in the financial and

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

credit markets may limit the availability of funding, refinancing or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect ourthe Company's liquidity and capital resources in the future.
3.  Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

The accompanying condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States (“U.S.”) of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U. S. Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements.

The condensed consolidated balance sheet at June 30, 2020,2021, condensed consolidated statements of operations for the three and six months ended June 30, 2021 and 2020, condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2021 and 2020, condensed consolidated statement of changes in stockholders' equity for the three and six months ended June 30, 2021 and 2020, and 2019, condensed consolidated statements of cash flows for the six months ended June 30, 20202021 and 2019, and condensed consolidated statement of changes in shareholder’s equity for the three and six months ended June 30, 2020 and 2019 are unaudited, but include all adjustments, consisting of normal recurring adjustments, that the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three and six months ended June 30, 20202021 are not necessarily indicative of results to be expected for the year ending December 31, 20202021 or for any future interim period. The condensed consolidated balance sheet at December 31, 20192020 has been derived from audited financial statements, however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 20192020 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 20192020 as filed with the SEC on Form 10-K on March 17, 2020.31, 2021. The Company’s consolidated subsidiaries consisted of its wholly-owned subsidiaries, Rockwell Transportation, Inc. and Rockwell Medical India Private Limited.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation.
Certain reclassifications have been made to the 2019 financial statements and notes to conform to the 2020 presentation.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Leases
The Company accounts for its leases under Accounting Standards Codification (“ASC”) 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred.
9

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election and recognizes rent expense on a straight-line basis over the lease term.
Loss Per Share

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

ASC 260, Earnings Per Share, requires dual presentation of basic and diluted earnings per share (“EPS”), with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that are then sharing in the earnings of the entity.
Basic net loss per share of common stock excludes dilution and is computed by dividing the net loss by the weighted average number of shares outstanding during the period. Diluted net loss per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. The Company has only incurred losses, therefore, basic and diluted net loss per share is the same. Securities that could potentially dilute net income per share in the future that were not included in the computation of diluted loss per share were as follows:
 As of June 30,
 2020 2019
Options to purchase common stock6,225,562
 8,187,161
Unvested restricted stock awards146,800
 146,800
Unvested restricted stock units503,395
 1,658,205
Warrants to purchase common stock3,248,054
 2,770,781
 10,123,811
 12,762,947

As of June 30,
20212020
Options to purchase common stock6,070,801 6,225,562 
Unvested restricted stock awards78,300 146,800 
Unvested restricted stock units342,604 503,395 
Warrants to purchase common stock26,426,863 3,248,054 
Total32,918,568 10,123,811 
Adoption of Recent Accounting Pronouncements
The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a review to determine the consequences of the change to its consolidated financial statements and assures that there are sufficient controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.
In April 2021, the Financial Accounting Standards Board ("FASB") recently issued Accounting Standards Update ("ASU") 2021-04 to codify the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.
4.  Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

•Step 1: Identify the contract with the customer
•Step 2: Identify the performance obligations in the contract
•Step 3: Determine the transaction price
•Step 4: Allocate the transaction price to the performance obligations in the contract
10

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
•Step 5: Recognize revenue when the company satisfies a performance obligation
Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue.
Shipping and handling costs associated with outbound freight related to contracts with customers are accounted for as a fulfillment cost and are included in cost of sales when control of the goods transfers to the customer.
Nature of goods and services
The following is a description of principal activities from which the Company generates its revenue.
Product sales –The Company accounts for individual products and services separately if they are distinct (i.e., if a product or service is separately identifiable from other items and if a customer can benefit from it on its own or with other resources that are readily available to the customer). The consideration, including any discounts, is allocated between separate products and

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

services based on their stand-alone selling prices. The stand-alone selling prices are determined based on the cost plus margin approach.
Drug and dialysis concentrate products are sold directly to dialysis clinics and to wholesale distributors in both domestic and international markets. Distribution and license agreements for which upfront fees are received are evaluated upon execution or modification of the agreement to determine if the agreement creates a separate performance obligation from the underlying product sales.  For all existing distribution and license agreements, the distribution and license agreement is not a distinct performance obligation from the product sales.  In instances where regulatory approval of the product has not been established and the Company does not have sufficient experience with the foreign regulatory body to conclude that regulatory approval is probable, the revenue for the performance obligation is recognized over the term of the license agreement (over time recognition). Conversely, when regulatory approval already exists or is probable, revenue is recognized at the point in time that control of the product transfers to the customer.
The Company received upfront fees under 35 distribution and license agreements that have been deferred as a contract liability.  The amounts received from Wanbang Biopharmaceuticals Co., Ltd. (“Wanbang”) and amounts to be received from, Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), Jeil Pharmaceutical Co., Ltd. ("Jeil Pharma") and Drogsan Pharmaceuticals ("Drogsan Pharma") are recognized as revenue over the estimated term of the applicable distribution and license agreement as regulatory approval was not received and the Company did not have sufficient experience in China, India and India,South Korea, respectively, to determine that regulatory approval was probable as of the execution of the agreement.  The amounts received from Baxter Healthcare Corporation (“Baxter”), are recognized as revenue at the point in time that the estimated product sales under the agreement occur. 
For the business under the Company’s distribution agreementDistribution Agreement with Baxter (the “Baxter Agreement”), and for the majority of the Company’s international customers, the Company recognizes revenue at the shipping point, which is generally the Company’s plant or warehouse. For other business, the Company recognizes revenue based on when the customer takes control or receipt of the product. The amount of revenue recognized is based on the purchase order less returns and adjusted for any rebates, discounts, chargebacks or other amounts paid to customers. There were no such adjustments for the periods reported. Customers typically pay for the product based on customary business practices with payment terms averaging 30 days, while distributor payment terms average 45 days.
Disaggregation of revenue
Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.
11
In thousands of US dollars ($) Three Months Ended June 30, 2020 Six Months Ended June 30, 2020
Products By Geographic AreaTotal U.S. Rest of World Total U.S. Rest of World
Drug Revenues           
Product Sales – Point-in-time$182
 $182
 $—
 $381
 $381
 $—
License Fee – Over time56
 —
 56
 112
 —
 112
Total Drug Products238

182

56
 493
 381
 112
Concentrate Products           
Product Sales – Point-in-time15,168
 13,319
 1,849
 30,280
 26,826
 3,454
License Fee – Over time490
 490
 —
 980
 980
 —
Total Concentrate Products15,658
 13,809
 1,849
 31,260
 27,806
 3,454
Net Revenue$15,896
 $13,991
 $1,905
 $31,753
 $28,187
 $3,566


ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

In thousands of U.S. dollars ($) Three Months Ended June 30, 2021Six Months Ended June 30, 2021
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$215 $215 $0 $439 $439 $0 
License Fee – Over time58 0 58 117 0 117 
Total Drug Products273 215 58 556 439 117 
Concentrate Products
Product Sales – Point-in-time14,379 13,026 1,353 29,084 26,227 2,857 
License Fee – Over time485 485 0 971 971 0 
Total Concentrate Products14,864 13,511 1,353 30,055 27,198 2,857 
Net Revenue$15,137 $13,726 $1,411 $30,611 $27,637 $2,974 
In thousands of US dollars ($)Three Months Ended June 30, 2019 Six Months Ended June 30, 2019
Products By Geographic AreaTotal U.S. Rest of World Total U.S. Rest of World
Drug Revenues           
Product Sales – Point-in-time$15
 $15
 $—
 $15
 $15
 $—
License Fee – Over time$68
 $—
 68
 136
 —
 136
Total Drug Products83
 15
 68
 151
 15
 136
Concentrate Products           
Product Sales – Point-in-time14,268
 12,822
 1,446
 29,264
 25,746
 3,518
License Fee – Over time495
 495
 —
 990
 990
 —
Total Concentrate Products14,763
 13,317
 1,446
 30,254
 26,736
 3,518
Net Revenue$14,846
 $13,332
 $1,514
 $30,405
 $26,751
 $3,654

In thousands of U.S. dollars ($)Three Months Ended June 30, 2020Six Months Ended June 30, 2020
Products By Geographic AreaTotalU.S.Rest of WorldTotalU.S.Rest of World
Drug Revenues
Product Sales – Point-in-time$182 $182 $0 $381 $381 $0 
License Fee – Over time56 0 56 112 0 112 
Total Drug Products238 182 56 493 381 112 
Concentrate Products
Product Sales – Point-in-time15,168 13,319 1,849 30,280 26,826 3,454 
License Fee – Over time490 490 0 980 980 0 
Total Concentrate Products15,658 13,809 1,849 31,260 27,806 3,454 
Net Revenue$15,896 $13,991 $1,905 $31,753 $28,187 $3,566 
Contract balances
The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.
In thousands of US dollars ($)June 30, 2020 December 31, 2019
Receivables, which are included in "Trade and other receivables"$3,565
 $4,203
Contract liabilities$11,084
 $12,076

In thousands of U.S. dollars ($)June 30, 2021December 31, 2020
Receivables, which are included in "Trade and other receivables"$5,357 $4,171 
Contract liabilities$9,103 $10,190 
There were 0 material losses recognized related to any receivables arising from the Company’s contracts with customers for the three and six months ended June 30, 20202021 and 2019.2020.
For the three and six months ended June 30, 20202021 and June 30, 2019,2020, the Company did not recognize any material bad-debt expense. There were 0 material contract assets recorded on the condensed consolidated balance sheet as of June 30, 20202021 and December 31, 2019.2020.  The Company does not generally accept returns of its concentrate products and 0 material reserve for returns of concentrate products was established as of June 30, 20202021 or December 31, 2019.2020. 
The contract liabilities primarily relate to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products
Transaction price allocated to remaining performance obligations
For the three and six months ended June 30, 2020,2021, revenue recognized from performance obligations related to prior periods was not material.
12

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts that have an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, totaled $11.1$9.1 million as of June 30, 2020.2021. The amount relates primarily to upfront payments and consideration received from customers that are received in advance of the customer assuming control of the related products. The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The Baxter Agreement includes minimum commitments of product sales over the duration of the agreement. Unfulfilled performance obligationsminimum commitments related to the Baxter Agreement are product sales of $8.2$6.2 million as of June 30, 2020,2021, which is being amortized ratably through expiration of the Baxter Agreement on October 2, 2024.
5.  Investments - Available-for-Sale
Investments available-for-sale consisted of the following as of June 30, 20202021 and December 31, 2019:2020 (table in thousands):
June 30, 2021
Amortized CostUnrealized GainUnrealized LossAccrued Interest IncomeFair Value
Available-for-Sale Securities
Bonds$8,558 $1 $0 $15 $8,574 
 June 30, 2020
 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Income Fair Value
Available-for-Sale Securities         
Bonds$13,172,049
 $14,468
 $(447) $72,127
 $13,258,197
 December 31, 2019
 Amortized Cost Unrealized Gain Unrealized Loss Accrued Interest Fair Value
Available-for-Sale Securities         
Bonds$14,238,161
 $13,321
 $(1,306) $—
 $14,250,176

December 31, 2020
Amortized CostUnrealized GainUnrealized LossAccrued InterestFair Value
Available-for-Sale Securities
Bonds$9,987 $3 $0 $7 $9,997 
The fair value of investments available-for-sale are determined using quoted market prices from daily exchange-traded markets based on the closing price as of the balance sheet date and are classified as a Level 1 measurement under ASC 820 Fair Value Measurements.
As of June 30, 20202021 and December 31, 2019,2020, the amortized cost and estimated fair value of our available-for-sale securities were due within one year.
6.  Inventory

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Components of inventory, net of reserves, as of June 30, 20202021 and December 31, 20192020 are as follows:follows (table in thousands):
 June 30,
2020		 December 31,
2019
Raw Materials$3,041,887
 $2,471,234
Work in Process303,545
 184,382
Finished Goods2,032,745
 1,432,290
Total$5,378,177
 $4,087,906

June 30,
2021		December 31,
2020
Raw Materials$3,598 $3,112 
Work in Process265 172 
Finished Goods1,936 1,805 
Total$5,799 $5,089 
As of June 30, 2020, we2021, the Company classified $0.8$1.1 million of inventory as non-current, all of which was related to Triferic or the active pharmaceutical ingredient and raw materials for Triferic. As of June 30, 2020, we had2021, the total Triferic inventory aggregating $3.7 million, against which we had reserved $2.5net of reserve was $1.7 million.
The $1.2$1.7 million net value of Triferic inventory consisted of $0.2$0.3 million of Triferic Dialysate(dialysate) finished goods with expiration dates ranging from September 2021 to December 2020 to May 2021,2023, $0.5 million of Triferic API with estimated remaining shelf life extending through 2023,beyond 2021, and $0.5$0.9 million of raw materials for Triferic with estimated remaining shelf life extending beyond 2025.
13

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
7.  Property and Equipment
As of June 30, 20202021 and December 31, 2019,2020, the Company’s property and equipment consisted of the following:following (table in thousands):
 June 30,
2020		 December 31,
2019
Leasehold Improvements$1,175,986
 $1,162,328
Machinery and Equipment4,869,771
 4,672,724
Information Technology & Office Equipment1,822,260
 1,810,246
Laboratory Equipment652,676
 653,075
 8,520,693
 8,298,373
Accumulated Depreciation(6,214,231) (5,864,968)
Property and Equipment, net$2,306,462
 $2,433,405

June 30,
2021		December 31,
2020
Leasehold Improvements$1,196 $1,196 
Machinery and Equipment5,684 5,475 
Information Technology & Office Equipment1,847 1,831 
Laboratory Equipment676 676 
9,403 9,178 
Accumulated Depreciation(6,874)(6,536)
Property and Equipment, net$2,529 $2,642 
Depreciation expense for each of the three months ended June 30, 2020 and 2019 totaled $0.2 million. Depreciation expense for the six months ended June 30, 2021 and 2020 totaled $0.2 million and 2019 totaled $0.4 million.
8.  Accrued Liabilities
Accrued liabilities as of June 30, 20202021 and December 31, 20192020 consisted of the following:following (table in thousands):
 June 30,
2020		 December 31,
2019
Accrued Research & Development Expense$268,677
 $283,407
Accrued Compensation and Benefits2,032,651
 1,018,196
Accrued Legal Expenses116,578
 181,597
Accrued Marketing Expenses191,797
 61,164
Other Accrued Liabilities1,827,377
 2,973,368
Total Accrued Liabilities$4,437,080
 $4,517,732

June 30,
2021		December 31,
2020
Accrued Research & Development Expense$315 $232 
Accrued Compensation and Benefits1,420 2,500 
Accrued Unvouchered Receipts647 755 
Accrued Workers Compensation531 395 
Other Accrued Liabilities1,080 1,131 
Total Accrued Liabilities$3,993 $5,013 
9.  Deferred Revenue
In October 2014, the Company entered into the Baxter Agreement with Baxter and received an upfront fee of $20 million. The upfront fee was recorded as deferred revenue and is being recognized based on the proportion of product shipments to Baxter in each period, compared with total expected sales volume over the term of the Baxter Agreement, which expires in October 2024. The Company recognized revenue of approximately $0.5 million and $1.0 million for each of the three and six months ended June 30,

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

2020 2021 and 2019, respectively.2020. Deferred revenue related to the Baxter Agreement totaled $8.2$6.2 million as of June 30, 20202021 and $9.1$7.2 million as of December 31, 2019.2020.
If a “Refund Trigger Event” occurs under the Baxter Agreement weprior to December 31, 2021, Rockwell would be obligated to repay a portion25% of the upfront fee and any paid portion of the facility fee. In the event of a Refund Trigger Event occurring from April 1, 2020 to December 31, 2021, Baxter would be eligible for a 25% refund of the Baxter Agreement’s upfront fee. In addition, if Baxter terminates the Baxter Agreement because Baxter has been enjoined by a court of competent jurisdiction from selling in the United States any product covered by the Baxter Agreement due to a claim of intellectual property infringement or misappropriation relating to such product prior to the end of 2020, Baxter would be eligible for a partial refund of the upfront fee of $5.0 million. In no event does the Baxter Agreement require more than one refund be paid.
In 2016, the Company entered into a distribution and license agreement with Wanbang (the "Wanbang Agreement") and received an upfront fee of $4.0 million. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $53,000 and $0.1 million revenue for each of the three and six months ended June 30, 20202021 and 2019, respectively.2020. Deferred revenue related to the Wanbang Agreement totaled $2.9$2.6 million as of June 30, 20202021 and $3.0$2.7 million as of December 31, 2019.2020.

OnIn January 14, 2020, wethe Company entered into license and supply agreements with Sun Pharma (the "Sun Pharma Agreements"), for the rights to commercialize Triferic Dialysate(dialysate) (ferric pyrophosphate citrate) in India. Under the terms of the Sun Pharma Agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic Dialysate(dialysate) in India, and wethe Company will supply the product to Sun Pharma. In consideration for the license, wethe Company received an upfront fee of $0.1 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Sun Pharma, will guide the development and execution for Triferic Dialysate(dialysate) in
14

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
India. Sun Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of approximately $2,500 and $5,000 duringfor each of the three and six months ended June 30, 2021 and 2020. Deferred revenue related to the Sun Pharma Agreement totaled $85,000 and $90,000 as of June 30, 2021 and December 31, 2020, respectively.

In September 2020, the Company entered into a license and supply agreements with Jeil Pharma (the "Jeil Pharma Agreements"), for the rights to commercialize Triferic (dialysate) (ferric pyrophosphate citrate) in South Korea. Under the terms of the Jeil Pharma Agreements, Jeil Pharma will be the exclusive development and commercialization partner for Triferic (dialysate) in South Korea, and the Company will supply the product to Jeil Pharma. In consideration for the license, the Company received an upfront fee of $0.2 million, and will be eligible for milestone payments and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Jeil Pharma, will guide the development and execution for Triferic (dialysate) in South Korea. Jeil Pharma will be responsible for all clinical and regulatory approval, as well as commercialization activities. The upfront fee was recorded as deferred revenue and is being recognized as revenue based on the agreement term. The Company recognized revenue of $2,500 and NaN for the three months ended June 30, 2021 and 2020, respectively, and $5,000 and NaN for the six months ended June 30, 2021 and 2020, respectively. Deferred revenue related to the Jeil Pharma Agreement totaled approximately $0.2 million as of June 30, 2021 and December 31, 2020.

In June 2021, the Company entered into license and supply agreements with Drogsan Pharma (the "Drogsan Agreements"), for the rights to commercialize Triferic (dialysate) and Triferic AVNU in Turkey. Under the terms of the Drogsan Agreements, Drogsan Pharma will be the exclusive commercialization partner for Triferic (dialysate) and Triferic AVNU in Turkey. In consideration for the license, the Company is due to receive an upfront fee of $0.2 million, and will be eligible for milestone payment and royalties on net sales. A Joint Alliance Committee, comprised of members from the Company and Drogsan Pharma, will guide the execution for Triferic (dialysate) and Triferic AVNU in Turkey. Drogsan Pharma will be responsible for all regulatory approval and commercialization activities, and the Company will supply the product to Drogsan Pharma for Turkey. The upfront fee will be recorded as deferred revenue and will be recognized as revenue based on the agreement term.
10.  Stockholders’ Equity

The Company held its annual meeting of stockholders on May 18, 2020 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares of common stock issuable thereunder by 2,900,000 shares (the “Amended 2018 Plan”).
Preferred Stock
As of June 30, 20202021 and December 31, 2019,2020, there were 2,000,000 shares of preferred stock, $0.0001 par value per share, authorized and 0 shares of preferred stock issued or outstanding.
Common Stock
As of June 30, 20202021 and December 31, 2019,2020, there were 170,000,000 shares of common stock, $0.0001 par value per share, authorized and 70,156,92293,811,381 and 65,378,89093,573,165 shares issued and outstanding, respectively.
Controlled Equity Offering (or "At the Market" Offering)
On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent. The offering and sale of up to $40.0 million of the shares has been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the Company’s registration statement on Form S-3 (File No. 333-227363), which was originally filed with the SEC on September 14, 2018 and declared effective by the SEC on October 1, 2018, the base prospectus contained within the registration statement, and a prospectus supplement that was filed with the SEC on March 22, 2019.
Sales of the shares, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an “at the market" offering as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the Sales Agreement at any time.

15

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

During the yearthree and six months ended December 31, 2019,June 30, 2021, the Company has not sold 1,840,443 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5,383,079, at a weighted average selling price of approximately $2.92. The Company paid $309,479 in commissions and offering fees related to the sale of the common stock. For the six months ended June 30, 2020, the Company sold 987,716 of shares of its common stock pursuant to the Sales Agreement for gross proceeds of $2,034,073, at a weighted average selling price of approximately $2.06. The Company paid $56,443 in commissions and offering fees related to the sale of common stock.Agreement. Approximately $32.6$32.3 million remains available for sale under this facility.

We areThe Company is not required to sell any shares at any time during the term of the facility. OurThe Company's ability to sell common stock under the facility may be limited by several factors including, among other things, the trading volume of ourits common stock and certain black-out periods that wethe Company may impose upon the facility, among other things.
Public Offering of Common Stock

On February 4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald & Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the "Offering").

On February 19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.
11.  Stock-Based Compensation
The Company recognized total stock-based compensation expense during the three and six months ended June 30, 2021 and 2020 and 2019as follows (table in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Service-based awards:
Restricted stock units$78 $(4)$182 $234 
Stock option awards344 336 735 776 
422 332 917 1,010 
Performance-based awards:
Restricted stock awards0 0 (390)0 
Restricted stock units0 (1,197)0 (1,025)
Stock option awards11 (596)(330)(511)
11 (1,793)(720)(1,536)
Total$433 $(1,461)$197 $(526)
Restricted Stock
A summary of the Company’s restricted stock awards during the six months ended June 30, 2021 is as follows:
 Three Months Ended
June 30,		 Six Months Ended
June 30,
 2020 2019 2020 2019
Service-based awards:       
Restricted stock units$(4,127) $427,472
 $233,987
 $771,823
Stock option awards336,513
 547,139
 776,138
 1,199,163
 332,386
 974,611
 1,010,125
 1,970,986
Performance-based awards:       
Restricted stock units(1,196,713) 402,814
 (1,025,502) 801,202
Stock option awards(596,687) 123,901
 (510,791) 246,440
 (1,793,400) 526,715
 (1,536,293) 1,047,642
Total$(1,461,014) $1,501,326
 $(526,168) $3,018,628

Restricted Stock
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 2021146,800 $5.70 
Forfeited(68,500)$5.70 
Unvested at June 30, 202178,300 $5.70 
A summary of the Company’s restricted stock awards during the six months ended June 30, 2020 is as follows:
 Number of Shares 
Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020146,800
 $5.70
Unvested at June 30, 2020146,800
 $5.70
A summary of the Company’s restricted stock awards during the six months ended June 30, 2019 is as follows:

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

 Number of Shares 
Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2019146,800
 $5.70
Unvested at June 30, 2019146,800
 $5.70

Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020146,800 $5.70 
Unvested at June 30, 2020146,800 $5.70 
The fair value of restricted stock awards are measured based on their fair value on the date of grant and amortized over the vesting period of 20 months. As of June 30, 2020,2021, unvested restricted stock awards of 146,80078,300 were related to performance-based awards. The forfeited performance-based restricted stock awards of 68,500 was due to the termination of the Company's former Chief Science Officer on January 19, 2021. These forfeited awards reduced stock-based compensation expense by $0.4 million.
16

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Service-Based Restricted Stock Units
A summary of the Company’s service-based restricted stock units during the six months ended June 30, 20202021 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 2021265,494 $2.60 
Granted310,050 0.90 
Vested(221,474)2.38 
Forfeited(11,466)4.81 
Unvested at June 30, 2021342,604 $1.17 

Number of Shares
Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020463,786

$4.26
Granted188,904

2.09
Vested(128,460) 4.30
Forfeited(104,168)
4.66
Unvested at June 30, 2020420,062

$3.27

A summary of the Company’s service-based restricted stock units during the six months ended June 30, 20192020 is as follows:
 Number of Shares Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2019472,959
 $4.32
Granted199,938
 4.45
Forfeited(3,650) 4.81
Unvested at June 30, 2019669,247
 $4.36

Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020463,786 $4.26 
Granted188,904 2.09 
Vested(104,168)4.66 
Forfeited(128,460)4.30 
Unvested at June 30, 2020420,062 $3.27 
The fair value of service based restricted stock units are measured based on their fair value on the date of grant and amortized over the vesting period. The vesting periods range from 1 to 3 years. Stock-based compensation expense of $0.1 million and $0.2 million was recognized for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense of NaN and $0.2 million was recognized duringfor the three and six months ended June 30, 2020, respectively. Stock-based compensation expense of $0.4 million and $0.8 million was recognized during the three and six months ended June 30, 2019, respectively. As of June 30, 2020,2021, the unrecognized stock-based compensation expense was $0.6$0.3 million, which is expected to be recognized over an estimated weighted average remaining term of less than 1 year. Included in the forfeited service-based restricted stock units are 96,541 units related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $0.2 million.
Performance-Based Restricted Stock Units
As of June 30, 2021, there were 0 outstanding performance-based restricted stock units.
A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2020 is as follows:
Number of SharesWeighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020988,958 $4.48 
Forfeited(905,625)4.61 
Unvested at June 30, 202083,333 $3.09 
Service-Based Stock Options
17

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)


Number of Shares
Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2020988,958

$4.48
Forfeited(905,625)

4.61
Unvested at June 30, 202083,333

$3.09

A summary of the Company’s performance-based restricted stock units during the six months ended June 30, 2019 is as follows:
 Number of Shares Weighted Average
Grant-Date
Fair Value
Unvested at January 1, 2019988,958
 $4.48
Unvested at June 30, 2019988,958
 $4.48


Stock-based compensation expense recognized for performance-based restricted stock units was ($1.2) million and ($1.0) million during the three and six months ended June 30, 2020 and $0.4 million and $0.8 million for the three and six months ended June 30, 2019, respectively. As of June 30, 2020, the unrecognized stock-based compensation expense related to performance-based restricted stock units was $0.1 million, which is expected to be recognized over an estimated weighted average remaining term of 2 years. The forfeited performance-based restricted stock awards of 905,625 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $1.3 million.
Service-Based Stock Options
The fair value of the service-based stock options granted for the six months ended June 30, 20202021 were based on the following assumptions:
June 30,
2021
Exercise priceJune 30,
2020$0.90 - $0.94
Exercise price$1.77 - $2.45
Expected stock price volatility68.2%75.8% - 74.4%77.7%
Risk-free interest rate0.35%0.47% - 1.65%1.06%
Term (years)5.5 -6.5- 6

A summary of the Company’s service-based stock option activity for the six months ended June 30, 2021 is as follows:

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Shares
Underlying
Options		Weighted
Average Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding at January 1, 20215,717,956 $4.55 6.6$0 
Granted1,522,162 0.96 6.0— 
Forfeited(277,764)2.52 — — 
  Expired(1,266,553)7.35 — — 
Outstanding at June 30, 20215,695,801 $3.07 7.8$5,000 
Exercisable at June 30, 20212,387,440 $5.25 5.8$0 
A summary of the Company’s service-based stock option activity for the six months ended June 30, 2020 is as follows:
 
Shares
Underlying
Options
 
Weighted
Average Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 20208,210,024
 $7.06
 5.1
 $107,150
Granted1,610,344
 2.24
 5.9
 —
Forfeited(211,471) 4.41
 —
 —
  Expired(3,983,335)
8.30

—

—
Outstanding at June 30, 20205,625,562
 $4.90
 6.7
 $1,100
        
Exercisable at June 30, 20202,809,954
 $7.09
 4.3
 $—
A summary of the Company’s service-based stock option activity for the six months ended June 30, 2019 is as follows:
 
Shares
Underlying
Options
 
Weighted
Average Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding at January 1, 20197,856,480
 $7.50
 5.2
 $—
Granted523,105
 4.33
 9.7
 —
Exercised(30,000) 4.93
 —
 —
  Forfeited(550,549)
6.67

—

—
Outstanding at June 307,799,036
 $7.36
 5.4
 $2,500
        
Exercisable at June 30, 20196,183,193
 $8.16
 4.3
 $—

Shares
Underlying
Options		Weighted
Average Exercise
Price		Weighted
Average
Remaining
Contractual
Term		Aggregate
Intrinsic
Value
Outstanding at January 1, 20208,210,024 $7.06 5.1$107,000 
Granted1,610,344 2.24 5.9— 
Forfeited(211,471)4.41 — — 
Expired(3,983,335)8.30 — — 
Outstanding at June 30, 20205,625,562 $4.90 6.7$1,000 
Exercisable at June 30, 20202,809,954 $7.09 4.3$0 
The aggregate intrinsic value in the table above is calculated as the difference between the closing price of ourthe Company's common stock and the exercise price of the stock options that had strike prices below the closing price.
During the six months ended June 30, 2020,2021, the Company granted stock options to purchase up to 1,610,3441,522,162 shares of common stock to certain employees. During the six months ended June 30, 2020, 211,4712021, 277,764 shares were forfeited.forfeited and 1,266,553 shares expired. Forfeitures are recorded in the period of occurrence; compensation expense is adjusted accordingly.
Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.7 million for the three and six months ended June 30, 2021, respectively. Stock-based compensation expense recognized for service-based stock options was $0.3 million and $0.8 million for the three and six months ended June 30, 2020, respectively. Stock-based compensation expense recognized for service-based stock options was $0.5 million and $1.2 million for the three and six months ended June 30, 2019, respectively. As of June 30, 2020,2021, total stock-based compensation expense related to unvested options not yet recognized totaled approximately $3.1$2.0 million, which is expected to be recognized over an estimated weighted average remaining term of 1.43.0 years. Included in the forfeited service-based stock options are 129,375 unvested options related to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited awards reduced stock-based compensation expense by $0.2 million. Included in the expired service-based stock options are 3,783,335 options related to the settlement with the former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. See Note 14 for further details.
Performance-Based Stock Options
18

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A summary of the performance-based stock options for the six months ended June 30, 2021 is as follows:
Number of SharesWeighted Average
Exercise
Price
Outstanding at January 1, 2021750,000 $2.20 
Expired(375,000)2.20 
Outstanding at June 30, 2021375,000 $2.20 
Exercisable at June 30, 20210 $0 
A summary of the performance-based stock options for the six months ended June 30, 2020 is as follows:

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)


Number of Shares
Weighted Average
Exercise
Price
Outstanding at January 1, 2020388,125

$4.70
Granted600,000
 2.45
Forfeited(388,125) 4.70
Outstanding at June 30, 2020600,000

$2.45






Exercisable at June 30, 2020—

$—
A summary of the performance-based stock options for the six months ended June 30, 2019 is as follows:
 Number of Shares Weighted Average
Exercise
Price
Outstanding at January 1, 2019388,125
 $4.70
Outstanding at June 30, 2019388,125
 $4.70
    
Exercisable at June 30, 2019—
 $—

Number of SharesWeighted Average
Exercise
Price
Outstanding at January 1, 2020388,125 $4.70 
Granted600,000 $2.45 
Forfeited(388,125)$4.70 
Outstanding at June 30, 2020600,000 $2.45 
Exercisable at June 30, 20200 $0 
Stock-based compensation expense recognized for performance-based stock options was ($0.6) millionNaN and ($0.5)$(0.3) million for the three and six months ended June 30, 2020.2021, respectively. Stock-based compensation expense recognized for performance-based stock options was $0.1$(0.6) million and $0.2$(0.5) million duringfor the three and six months ended June 30, 2019.2020, respectively. The reduction in stock-based compensation expense was due to the performance criteria of certain performance-based options granted to officers of the Company becoming non-probable as of March 31, 2021. The Company will continue to assess the probability of the performance criteria until such time the criteria becomes probable and the performance-based stock option vests or continues to be non-probable and the performance-based stock option expires. As of June 30, 2020, the2021, there was 0 unrecognized stock-based compensation expense related to unvested performance-based stock options was $0.1 million. The forfeited unvested performance-based stock options of 388,125 is due to the resignation of the Company's former President and Chief Executive Officer on April 17, 2020. These forfeited options reduced stock-based compensation expense by $0.7 million.options.
12.  Related Party TransactionsLicensing Agreements
Product License Agreements
The Company is a party to a Licensing Agreement with Charak, LLC ("Charak") dated January 7, 2002 (the "2002 Agreement") that grants the Company exclusive worldwide rights to certain patents and information related to our Triferic® product. On October 7, 2018, the Company entered into a Master Services and IP Agreement (the “Charak MSA”) with Charak and Dr. Ajay Gupta, who serves as Executive Vice President and Chief Scientifica former Officer of the Company. Pursuant to the MSA, the parties entered into 3 additional agreements described below related to the license of certain soluble ferric pyrophosphate (“SFP”) intellectual property owned by Charak, as well as the Employment Agreement (defined below).Charak. The Charak MSA provided for a payment of $1.0 million to Dr. Gupta, payable in 4 quarterly installments of $250,000 each on October 15, 2018, January 15, 2019, April 15, 2019 and July 15, 2019, and reimbursement for certain legal fees incurred in connection with the Charak MSA. The Company recorded $1.1 million as Research and Development Expense - License Acquired (Related Party) for the twelve months ended December 31, 2018. The Company paid all four of the quarterly installments totaling $1.0 million and accrued $0.1 million for the reimbursement of certain legal expenses during the year ended December 31, 2019. As of December 31, 2020, the Company had fulfilled its reimbursement obligation of certain legal expenses. As of June 30, 2020, and December 31, 2019, the Company accrued $27,500 and $0.1 million, respectively, as a related party payable on the condensed consolidated balance sheet. In addition,2021, the Company accrued $0.2 million relating to certain IP reimbursement expenses as a related party payableand certain sublicense royalty fees within accrued liabilities on the condensed consolidated balance sheet.
Pursuant to the Charak MSA, the aforementioned parties entered into an Amendment, dated as of October 7, 2018 (the “Charak Amendment”), to the 2002 Agreement, under which Charak granted the Company an exclusive, worldwide, non-transferable license to commercialize SFP for the treatment of patients with renal failure. The Charak Amendment amends the royalty payments due to Charak under the 2002 Agreement such that the Company is liable to pay Charak royalties on net sales
19

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
by the Company of products developed under the license, which includes the Company’s Triferic® product, at a specified rate until December 31, 2021 and thereafter at a reduced rate from January 1, 2022 until February 1, 2034. Additionally, the Company

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

shall pay Charak a percentage of any sublicense income during the term of the agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and be no less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Commercialization and Technology License Agreement I.V. Triferic® (now Triferic AVNU), dated as of October 7, 2018 (the “IV Agreement”), under which Charak granted the Company an exclusive, sub-licensable, royalty-bearing license to SFP for the purpose of commercializing certain intravenous-delivered products incorporating SFP for the treatment of iron disorders worldwide for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. The Company is liable to pay Charak royalties on net sales by the Company of products developed under the license at a specified rate until December 31, 2021. From January 1, 2022 until February 1, 2034, the Company is liable to pay Charak a base royalty at a reduced rate on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the IV Agreement, which amount shall not be less than a minimum specified percentage of net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
Also pursuant to the Charak MSA, the Company and Charak entered into a Technology License Agreement TPN Triferic®, dated as of October 7, 2018 (the “TPN Agreement”), pursuant to which Charak granted the Company an exclusive, sublicensable, royalty-bearing license to SFP for the purpose of commercializing worldwide certain parenteral nutritional ("TPN”) products incorporating SFP. The license grant under the TPN Agreement continues for a term that expires on the later of February 1, 2034 or upon the expiration or termination of a valid claim of a licensed patent. During the term of the TPN Agreement, the Company is liable to pay Charak a base royalty on net sales and an additional royalty on net sales while there exists a valid claim of a licensed patent, on a country-by-country basis. The Company shall also pay to Charak a percentage of any sublicense income received during the term of the TPN Agreement, which amount shall not be less than a minimum royalty on net sales of the licensed products by the sub-licensee in jurisdictions where there exists a valid claim, on a country-by-country basis, and not be less than a lower rate of the net sales of the licensed products by the sub-licensee in jurisdictions where there exists no valid claim, on a country-by-country basis.
The transaction was accounted for as an asset acquisition pursuant to ASU 2017-1, Business Combinations (Topic 805), Clarifying the Definition of a Business, as the majority of the fair value of the assets acquired was concentrated in a group of similar assets, and the acquired assets did not have outputs or employees. The assets acquired under the Charak MSA include a license of SFP. Because SFP has not yet received regulatory approval, the $1.1 million purchase price paid and accrued for these assets has been expensed in the Company’s statement of operations for the year ended December 31, 2018. In addition, because the potential milestone payments are not yet considered probable, 0 milestone payments have been accrued at June 30, 2020.
13.  Leases
We lease ourThe Company leases its production facilities and administrative offices as well as certain equipment used in our operations including leases on transportation equipment used in the delivery of ourits products. The lease terms range from monthly to five years. We occupyThe Company occupies a 51,000 square foot facility and a 17,500 square foot facility in Wixom, Michigan under a lease expiring in August 2021. We2024. The Company also occupyoccupies two other manufacturing facilities, a 51,000 square foot facility in Grapevine, Texas under a lease expiring in December 2020,2025, and a 57,000 square foot facility in Greer, South Carolina under a lease expiring February 2023. In addition, we occupy a 1,408 square foot office space in Greer, South Carolina under a lease expiring April 2021. In addition, we executed a lease forthe Company occupies 4,100 square feet of office space in Hackensack, New Jersey withunder a lease term beginning on April 1, 2019 and expiring on July 1, 2024. This lease is currently being offered for sublease.
At June 30, 2021, the Company had operating and finance lease liabilities of $6.2 million and right-of-use assets of $6.1 million, which are included in the consolidated balance sheet.
At December 31, 2020, the Company had operating lease liabilities of $2.5$3.0 million and right-of-use assets of $2.4$2.9 million, which are included in the consolidated balance sheet.
The following summarizes quantitative information about the Company’s operating leases:leases (table in thousands):
20

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

 Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Six Months Ended June 30, 2020 Six Months Ended June 30, 2019
Operating leases       
Operating lease cost$403,077
 $554,921
 $845,905
 $1,089,888
Variable lease cost122,865
 78,237
 312,149
 168,081
Operating lease expense525,942
 633,158
 1,158,054
 1,257,969
Short-term lease rent expense4,157
 4,122
 8,313
 8,313
Total rent expense$530,099
 $637,280
 $1,166,367
 $1,266,282
        
Other information       
Operating cash flows from operating leases$410,092
 $514,116
 $854,785
 $1,038,081
Right of use assets exchanged for operating lease liabilities$—
 $821,195
 $—
 $4,305,428
Weighted-average remaining lease term – operating leases2.4
 2.6
 2.4
 2.6
Weighted-average discount rate – operating leases6.8% 6.8% 6.8% 6.8%

Three Months Ended June 30, 2021Three Months Ended June 30, 2020Six Months Ended June 30, 2021Six Months Ended June 30, 2020
Operating leases
Operating lease cost$432 $403 $851 $846 
Variable lease cost90 123 192 312 
Operating lease expense522 526 1,043 1,158 
Finance leases
Amortization of right-of-use assets67 0 112 0 
Interest on lease obligations20 0 33 0 
Finance lease expense87 0 145 0 
Short-term lease rent expense4 4 8 8 
Total rent expense$613 $530 $1,196 $1,166 
Other information
Operating cash flows from operating leases$428 $410 $853 $855 
Operating cash flows from finance leases$21 $0 $34 $0 
Financing cash flows from finance leases$56 $0 $93 $0 
Right of use assets exchanged for operating lease liabilities$1,476 $0 $3,371 $0 
Right of use assets exchanged for finance lease liabilities$316 $0 $777 $0 
Weighted-average remaining lease term – operating leases3.52.43.52.4
Weighted-average remaining lease term – finance leases5.50.05.50
Weighted-average discount rate – operating leases6.2 %6.8 %6.2 %6.8 %
Weighted-average discount rate – finance leases5.5 %0 %5.5 %0 %
Future minimum rental payments under operating lease agreements are as follows:follows (in thousands):
Year ending December 31, 2020 (remaining)$780,038
Year ending December 31, 20211,054,873
Year ending December 31, 2022591,925
Year ending December 31, 2023234,327
Year ending December 31, 202497,423
Total$2,758,586
Less present value discount(212,148)
Operating lease liabilities$2,546,438

OperatingFinance
Year ending December 31, 2021 (remaining)$865 $148 
Year ending December 31, 20221,603 300 
Year ending December 31, 20231,285 305 
Year ending December 31, 2024930 305 
Year ending December 31, 2025468 305 
Remaining future payments97 319 
Total$5,248 $1,682 
Less present value discount(522)(228)
Operating and finance lease liabilities$4,726 $1,454 
14.  Commitments and Contingencies

Demand Notice

In February 2020, the Company received a letter from a supplier relating to a supply agreement entered into with the Company in 2015.  The supplier alleged the Company did not meet certain annual minimums under the supply agreement, and has requested $3.0 million in penalties, plus payment of the cost for certain raw materials.  No lawsuit was filed. While the Company believed  it had several defenses to the supplier's claim, the Company and the supplier negotiated an amicable resolution of the dispute.  On July 31, 2020, the Company and the supplier entered into a settlement agreement, which released the Company from any penalties relating to annual minimums under the 2015 agreement, established new minimums under an amended supply agreement and required the Company to pay for certain raw materials with 50% of the cost to be paid upon execution of the settlement agreement and the remaining 50% to be paid no later than December 31, 2020.
Litigation
SEC Investigation
As a follow up to certain prior inquiries, the Company received a subpoena from the SEC during the Company’s quarter ended September 30, 20192018 requesting, among other things, certain information and documents relating to the status of the Company’s request to the Centers for Medicare & Medicaid Services (the "CMS") for separate reimbursement
21

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
status for Triferic Dialysate,(dialysate), the Company’s reserving methodology for expiring Triferic inventory, and the basis for the Board’s termination of the former Chief

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Executive Officer, Robert Chioini, and former Chief Financial Officer, Thomas Klema, in 2018. The Company is cooperating with the SEC and is responding to the SEC’s requests for documents and information.
Shareholder Class Action Lawsuits
On July 27, 2018, Plaintiff Ah Kit Too filed a putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and former officers, Robert Chioini and Thomas Klema (the "Too Complaint"). The Too Complaint is a federal securities class action purportedly brought on behalf of a class consisting of all persons and entities, other than Defendants, who purchased or otherwise acquired the publicly traded securities of the Company between March 16, 2018 and June 26, 2018. The Too Complaint alleges that the Company and Messrs. Chioini and Klema violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). Specifically, the Too Complaint alleges that defendants filed reports with the SEC that contained purported inaccurate and misleading statements regarding the potential for the Company’s drug, Triferic, to quality for separate reimbursement status by the CMS.
On September 4, 2018, Plaintiff Robert Spock filed a similar putative class action lawsuit in the United States District Court in the Eastern District of New York against the Company and Messrs. Chioini and Klema (the "Spock Complaint"). The Spock Complaint is a federal securities class action purportedly brought on behalf of a class consisting of persons who purchased the Company’s securities between November 8, 2017 and June 26, 2018. This complaint alleges that the Company and Messrs. Chioini and Klema violated the Exchange Act in that the Company was aware the CMS would not pursue the Company’s proposal for separate reimbursement for Triferic; misstated reserves in the Company’s quarterly report for the first quarter of 2018; had a material weakness its internal controls over financial reporting, which rendered those controls ineffective; Mr. Chioini withheld material information regarding Triferic from the Company’s auditor, corporate counsel, and independent directors of the Board; and, as a result of these alleged issues, statements about the Company’s business were materially false and misleading.
On September 25, 2018, four Company stockholders filed motions to appoint lead plaintiffs, lead counsel, and to consolidate the Ah Kit Too v. Rockwell securities class action with the Spock v. Rockwell securities class action.  On October 10, 2018, the court issued an order consolidating the two actions, appointing co-lead plaintiffs and co-lead counsel.  On December 10, 2018, lead Plaintiffs filed a consolidated amended complaint, which included the same allegations as the initial complaints and asserted claims on behalf of a putative class consisting of person who purchased the Company’s securities between November 8, 2017 and June 26, 2018.  On February 18, 2019, the Company answered the consolidated amended complaint.
On August 7, 2019, all parties to the class action entered into a settlement of the consolidated class action.  Pursuant to the terms and conditions of the settlement agreement, the Company will pay the Plaintiffs $3.7 million (the “Settlement Amount") in exchange for a full release of all liability as to all defendants. This resulted in a settlement expense of approximately $0.4 million for the year ended December 31, 2019. Of the Settlement Amount, the Company contributed approximately $0.1 million, which represented the remaining retention amount under the Company’s director and officer liability insurance policy as of June 30, 2020. The remainder of the settlement amount has been funded by the Company’s director and officer insurance policy. The settlement was approved by the court on February 26, 2020.
Shareholder Derivative Actions
Plaintiff Bill Le Clair filed a Verified Stockholder Derivative Complaint on April 23, 2019 in Case No. 1:19-cv-02373, and Plaintiff John Post filed a Verified Stockholder Derivative Complaint on May 10, 2019 in Case No. 1:19-cv-02774 (the “Derivative Complaints”) in the United States District Court in the Eastern District of New York, purportedly on behalf of the Company (as nominal defendant) and against certain of the Company’s current and former directors (the “Individual Defendants”).  The Derivative Complaints assert causes of actions against the Individual Defendants for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.  The Derivative Complaints allege the Individual Defendants breached duties by, among other things, permitting alleged misstatements to be made in public filings regarding the status of separate reimbursement for Triferic from CMS, the adequacy of the Company's reserves and internal controls.  The Derivative Complaints demand a jury trial, seeking monetary damages, corporate governance and internal procedure reform, injunctive relief on the Individual Directors’ trading activities, restitution, and attorneys’ fees.  The cases have been consolidated and the parties are in advanced settlement discussions.  If a settlement is not reached, the Defendants anticipate filing motions to dismiss.
The Company tendered the above shareholder derivative actions to its director and officer insurance carrier(s) for defense and indemnity under its applicable insurance policies. On May 18, 2020, the Company, the Individual Defendants and the Plaintiffs (the "Settling Parties") entered into a formal Stipulation of Settlement, which memorializes the terms of the Settling Parties'

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

settlement of the Derivative Complaints. On June 2, 2020, the court issued an order preliminarily approving the settlement. A hearing is set for August 10, 2020 to determine if the court should issue a final order approving the final settlement. The Company has exhausted self-insured retention under the above insurance policies. The Company’s director and officer insurance company has funded the settlement amount on behalf of the Company.
Termination of our former CEO and CFO
On August 7, 2018, the Company entered into a confidential settlement agreement and mutual release with Robert Chioini, its former Chief Executive Officer, Thomas Klema, its former Chief Financial Officer and a former and then current director. For more details see Note 15 in the Company’s Annual Report on Form 10-K filed on March 17, 2020.
15. Loan and Security Agreement

OnIn March 16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP ("Innovatus"), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will beis no longer eligible to draw on a second tranche of $5.0 million, uponwhich was tied to the achievement of certain milestones including the FDA approval of the Company’s New Drug Application for Triferic AVNU.by a specific date. The Company willmay be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.

The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum and an effective interest rate of 10.9%. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For each of the three months ended June 30, 2020 and 2019,2021 interest expense amounted to $0.5 million and NaN, respectively.$0.6 million. For the six months ended June 30, 20202021 and 2019,2020, interest expense amounted to $1.2 million and $0.6 million, and NaN, respectively.

The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. Proceeds will beare being used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if2020. The Company cannot assure you that we can maintain compliance with the covenants under our Loan Agreement, which may result in an event of default. The Company's ability to comply with these covenants may be adversely affected by events beyond its control. For example, the Loan Agreement contains certain financial covenants relating to sales and, as a result of the ongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company drawsmay not be able to satisfy such covenants in the second tranchefuture. If the Company is unable to comply with the covenants under the Loan Agreement, it would pursue all available cure options in order to regain compliance. The Company previously failed to satisfy a revenue covenant for the period ended December 31, 2020 and then subsequently agreed to an appropriate remedy during the applicable cure period. However, the Company may not be able to mutually agree with Innovatus on appropriate remedies to cure a future breach of $5.0 million.a covenant, which could give rise to an event of default. If the Company is unable to avoid an event of default, any required repayments could have an adverse effect on its liquidity. As of June 30, 2020,2021, the Company wasis in compliance with all the reporting and financial covenants. The financial statements for June 30, 2021 have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. Based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability.If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reevaluated for its classification and presentation.

In connection with each funding of the Term Loans, the Company is required to issue to Innovatus a warrant (the “Warrants”) to purchase a number of shares of the Company’s common stock equal to 3.5% of the principal amount of the relevant Term Loan funded divided by the exercise price, which will be based on the lower of (i) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the execution of the Loan Agreement or (ii) the closing price on the last trading day immediately preceding the execution of the Loan Agreement (or for the second and third tranches only at the lower of (i) $1.65 per share or (ii) the volume weighted average closing price of the Company’s stock for the 5-trading day period ending on the last trading day immediately preceding the relevant Term Loan funding). The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. The number of shares of common stock for which each Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in such Warrant. In connection with the first tranche of the Term Loans, the Company issued a Warrant to Innovatus, exercisable for an aggregate of 477,273 shares of the Company’s common stock at an exercise price of $1.65 per share. The Company evaluated the warrant under ASC 470, Debt, and recognized an additional debt discount of approximately $0.5 million based on the relative fair value of the base instruments and warrants. The Company calculated the fair value of the warrant using the Black-Scholes model.
22

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

As of June 30, 2020,2021, the outstanding balance of the Term Loan was $20.8$21.1 million, net of unamortized issuance costs and unaccreted discount of $1.7$1.4 million.

The following table reflects the schedule of principal payments on the Term Loan as of June 30, 2020:2021 (in thousands):

Principal Payments
2021$0 
20222,250 
20239,000 
20249,000 
20252,250 
$22,500 

ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

 Principal Payments
2020$—
2021—
20222,250,000
20239,000,000
20249,000,000
20252,250,000
 $22,500,000


16. Subsequent Events

Resignation of Chief Financial Officer
On June 5, 2020, Angus Smith, the Company's Chief Financial Officer, notifiedJuly 3, 2021, the Company of his intententered into a short-term note payable for $2.0 million, bearing interest at 3.925% per annum to resign from the Company effectivefinance various insurance policies. Principal and interest payments related to this note will begin on July 3, 2020. As2021 and are paid on a result of Mr. Smith's resignation, certain of his time-based, all of his performance-based and market-based stock awards previously granted to Mr. Smith will be forfeited. Such forfeitures will be reflected instraight-line amortization over a 9-month period with the Company’s Quarterly Reportfinal payment due on Form 10-Q for the quarter ended September 30, 2020. The estimated expense the forfeited stock awards is approximately $0.7 million.March 3, 2022.

23

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes in “Item 1. Condensed Consolidated Financial Statements”. References in this report to "Rockwell," the “Company,” “we,” “our” and “us” are references to Rockwell Medical, Inc. and its subsidiaries.
Forward-Looking Statements
We make forward-looking statements in this report and may make such statements in future filings with the Securities and Exchange Commission, or SEC.  We may also make forward-looking statements in our press releases or other public or shareholder communications.  Our forward-looking statements are subject to risks and uncertainties and include information about our expectations and possible or assumed future results of our operations.  When we use words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend,” or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. Our forward looking statements also include, without limitation, statements about our liquidity and capital resources; our plans and ability to successfully commercialize our products; our timing and ability to obtain add-on reimbursement for our products; our ability to successfully launch FDA approvedFDA-approved Triferic AVNU; whether we canour ability to develop FPC for other indications; our ability to successfully execute on our business strategy and development of new indications; and statements regarding our anticipated future financial condition, operating results, cash flows and business plans.
While we believe that our forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements, which are based on information available to us on the date of this report or, if made elsewhere, as of the date made.  Because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different.  Factors that might cause such a difference include, without limitation, the risks and uncertainties discussed in this report, “Item 1A — Risk Factors” in our Form 10-K for the year ended December 31, 20192020 and from time to time in our other reports filed with the SEC, including in this Form 10-Q.
Other factors not currently anticipated may also materially and adversely affect our results of operations, cash flow and financial position.  There can be no assurance that future results will meet expectations.  Forward-looking statements speak only as of the date of this report and we expressly disclaim any intent to update or alter any statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.
Overview and Recent Developments

Rockwell is a commercial-stage, biopharmaceutical company developing and commercializing our next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate ("FPC"), which we believe has the potential to lead to transformative treatments for iron deficiency in multiple disease states, that we believe could reduce healthcare costs and improve patients’ lives. We are also one of the two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.
We have two novel, FDA approved therapies, Triferic and Triferic AVNU, which are the first two products developed from our FPC platform. We are marketing both products to kidney dialysis centers for their patients receiving dialysis. In 2021, we intend to advance our FPC platform strategy outside of dialysis by starting a Phase 2 trial for the treatment of iron deficiency anemia in patients who are receiving long-term and or chronic intravenous(“IV”) medications for various therapeutic needs in the home infusion setting.. The trend toward providing medical care, including the delivery of medicines, at home make the home infusion market a rapidly growing area of healthcare. We believe that the home infusion setting is a natural path for expansion of our platform as many of the patients suffer from chronic diseases that are associated with iron deficiency and anemia. We are currently seeking additional FDA feedback and clarification regarding the clinical development plan for FPC in the home-infusion setting. Our expectations regarding the commencement of a Phase 2 trial in 2021 is based on the assumption that the FDA agrees with the development plan as we have proposed. In our R&D pipeline, we are also investigating FPC’s impact on iron deficiency in the treatment of hospitalized patients with acute heart failure, with the potential to begin another Phase 2 trial in these patients in 2022.
We are the second largest supplier of hemodialysis concentrates in the United States, with a biopharmaceutical companyreputation for excellent service, quality, and reliability. We believe that this reputation, which is based on over 25 years of service to the kidney
24

dialysis centers, combined with about $60 million in annual revenue, approximately 300 dedicated employees, expertise in manufacturing and logistics and the added expertise in pharmaceutical development and commercialization brought to the Company by recent additions to our management team, gives us a solid foundation on which to grow.
At Rockwell Medical, we are dedicated to transformingreplacing the currently inadequate standard of care for treatment of iron deficiency in acute and chronic disease by leveraging our proprietary FPC platform technology. We believe that our proprietary drug platform, FPC, is a next-generation parenteral iron therapeutic that has several advantages over other parenteral iron therapies. Importantly, it provides iron that is immediately bioavailable for critical body processes once it is administered. It has been demonstrated to be safe and well-tolerated, with a safety profile similar to placebo.
Iron deficiency, which is often overlooked and undertreated in several illnesses because of the difficulty in treating them, can develop into a serious medical condition when left untreated. It is a common comorbidity in many disease states, such as end-stage kidney disease, chronic kidney disease, acute heart failure, cancer and multiple chronic gastrointestinal conditions. Iron deficiency impacts patients’ health in many ways, including anemia, organ dysfunction, slower recovery, diminished energy and reduced quality of life.

Strategy Evolution and Overview
Rockwell Medical has evolved its strategy over the past year to develop into a more medically-, scientifically- and data-driven company. We believe future clinical, regulatory and commercial success require the right people with the right experience to navigate us to the right data. There has been an evolution of both our management and board, providing us with greater relevant experience. In particular, we have added board members and employees with significant medical and commercial experience in iron deficiency anemia and improving outcomesthe dialysis sector, drug development and commercialization, small-cap public company finance and management and clinical nurse educator patient support. We believe these changes support an improved execution of our strategy to generate data that will support future commercial growth, fair reimbursement and regulatory approvals.
Our strategy is to accelerate Rockwell’s growth by creating and developing pharmaceutical products based on our FPC technology for disease states where patients acrosscan benefit the globe, withmost from an initial focuseffective treatment for iron deficiency or iron deficiency anemia, while concurrently refining our dialysis business to drive incremental growth and efficiencies. We plan to leverage and build on ESKD.the foundation provided by our current dialysis business serving kidney dialysis centers by developing a pipeline of additional potential drug therapies in multiple disease states outside of nephrology. We have preliminarily identified three disease states where we believe FPC may have the biggest impact.
Dialysis Business: We are also a manufacturerthe second largest supplier, and one of the two major suppliers of hemodialysis concentrates in the United States. We manufacture, sell and deliver hemodialysis concentrates, which are used to maintain human life by removing toxins and balancing electrolytes in the dialysis patient’s bloodstream. We have core capabilities in manufacturing hemodialysis concentrates in three facilities, totaling 159,000 square feet, located in Michigan, Texas and South Carolina. We also have core capabilities in the logistics of delivering these products to dialysis clinics throughout most of the United States.
Our first two branded products from our FPC platform, Triferic® (dialysate) and Triferic AVNU® (IV), are used to maintain hemoglobin in patients undergoing hemodialysis. We are building on our reputation and industry presence by commercializing then to medium and small dialysis organizations. We began commercializing Triferic and Triferic AVNU in the United States in the second half of 2019 and in early 2021, respectively. In April 2021, we received marketing approval for Triferic AVNU from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, which is the first international regulatory approval for our intravenous therapy. We expect Triferic AVNU to become commercially available in Canada during 2022. Our strategy for increasing Triferic adoption is to continue to generate data in clinics showing the benefits of Triferic in real world protocols. In addition, we expect to study Triferic use with the innovations that we believe have the potential to change future medical practices (e.g. introduction and adoption of HIF-PHIs), subject to FDA approval. We believe that positive data from these studies would better position Triferic for long-term growth. We are developing strategic alliance partners for development, regulatory approval and commercialization of Triferic outside of the United States.
Home Infusion Program: We plan to initiate a clinical trial program of FPC for the treatment of iron deficiency anemia in the home-infusion setting. Many patient groups requiring home infusion therapies suffer from chronic diseases that
25

are associated with a high incidence of iron deficiency and anemia. Home infusion represents a large and rapidly-growing segment of healthcare where we believe FPC may have distinct advantages over currently available iron replacement therapy options.
Pipeline Development: We are investigating the use of our FPC platform for the treatment of iron deficiency in hospitalized patients with acute heart failure. We believe that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics. This effect could help patients recover faster, resulting in shorter hospital stays and fewer 30-day re-admissions, which would be a meaningful reduction healthcare costs and human suffering.
Our Growth Strategy
We plan to accelerate our growth by combining the solid foundation, strength and reputation of our dialysis providersbusiness with the high-growth potential from therapeutics derived (or generated) from our FPC platform in multiple disease states where patients can benefit the most from an effective treatment for iron deficiency. In parallel with continually seeking to drive incremental growth and distributorsefficiencies in our dialysis business unit, our strategy is to accelerate the growth of our business in large, higher-margin markets by creating and developing pharmaceutical products based on our proprietary FPC technology that address iron deficiency in patients who are currently under-treated.
Dialysis Business
We are one of the two major suppliers of hemodialysis concentrates in the United States. Over the past 25 years we have developed a core expertise in manufacturing and delivering hemodialysis concentrates. Because these concentrates are used to maintain human life by removing toxins and balancing electrolytes in the dialysis patient’s bloodstream, we manufacture them under cGMP regulations as described below. Our concentrates are manufactured in three facilities, totaling 159,000 square feet, located in Michigan, Texas and South Carolina, from which we deliver these products to dialysis clinics throughout most of the United States. We utilize our own delivery fleet as well as third parties. We employ approximately 300 people in the concentrates unit of our dialysis business.
The “Rockwell Medical” name has earned a reputation for dependability, quality and service within our customer base. This reputation was further strengthened during the recent challenges presented, not only by the COVID-19 pandemic, but also by the multitude of recent natural disasters where our team has been challenged by hurricanes, flooding and freezing, while still meeting production demands.
Our dialysis business in concentrates and our growth opportunities with FPC technology are synergistic. We are leveraging our leadership position in the dialysis sector to commercialize our first two FPC-based products, Triferic and Triferic AVNU, which are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. We commercialize the Triferic products ourselves in the United States, and abroad. We supplyare partnering with established local pharmaceutical companies for the domestic marketregulatory approval and commercialization outside of the United States.
Although we have an excellent reputation for dependability and service within the dialysis sector, with dialysis concentrates and Triferic, our growth opportunities for both in the United States dialysis market are challenged by the consolidated ownership of dialysis clinics, a capitated reimbursement model and the demographics of the patient population. The two largest dialysis organizations treat approximately 73% of the patients in the United States. One manufactures its own concentrates and IV iron and we alsoalready supply dialysis concentrates to distributors servingthe other. Through our partnership with Baxter International, we currently supply concentrates to a numbersignificant percentage of foreign countries, primarilythe small and medium sized dialysis organizations. In a sector, such as kidney dialysis, with capitated reimbursement for the dialysis procedure and all included inputs, new product success depends on compelling data demonstrating improved patient outcomes and/or pharmacoeconomics versus the current standard of care in practice in the Americasclinics. Once Medicare determined that Triferic and Triferic AVNU would be reimbursed under the Pacific Rim. Substantially, allfixed bundled rate, market adoption became more dependent on the generation of our sales have been concentrate products and ancillary items, though we initiated commercial sales of our proprietary therapeutic, Triferic Dialysate, during the second quarter of 2019.

We are focused on developing our proprietary ferric pyrophosphate (“FPC”) therapeutic platform, and the first product developed from this platform is Triferic, the first-FDA approved productthese data, which were not required for the replacementdrug's approval from the FDA.
Notwithstanding the growth limitations mentioned above, we have made progress and continue to be confident that Triferic has the potential to be the treatment of iron andchoice for the maintenance of hemoglobin in adultdialysis patients. Toward this end, we have increased our efforts in generating real world data in clinics with current protocols, which we believe will help with the adoption of Triferic and Triferic AVNU as these results are developed and disseminated over time. In addition, we believe the hemodialysis patients. Our missionindustry may experience a great deal of change over the next several years. We plan to take the steps necessary to
26

generate the data necessary to potentially allow Triferic and Triferic AVNU to benefit from these new innovations, such as the potential approval of a class of drugs, known as hypoxia-inducible factor prolyl hydroxylase inhibitors ("HIF-PHIs"), as well as the new, solid-state dialysis equipment in development. We are planning to study Triferic in combination with these potential new innovations as they become available.
A key element of our dialysis business strategy is to also improve the strength of our concentrates business by creating efficiencies and enhancing our manufacturing and transportation operations. We have launched projects to identify ways to improve the overall profitability of these core operations. Specifically, we are reviewing our entire supply chain to identify opportunities for improvement, prioritizing initiatives that will have the largest impact on long-term efficiency, profitability and growth.
Home Infusion
Our growth strategy is to go beyond our foundational business in dialysis by leveraging the pre-clinical, clinical pharmacology and safety data from Triferic. We are planning to develop an FPC-based therapeutic for iron deficiency to be given in the home infusion setting. According to the National Home Infusion Association, the number of patients served by home infusion therapy has grown from approximately 800,000 in 2010 to over 3,000,000 in 2019. The home infusion setting is expected to continue to expand, which has been further accelerated by the COVID-19 pandemic and commercialize the desire to reduce or eliminate hospital and or clinic exposure. Many patient groups requiring home infusion therapies suffer from diseases that are associated with an incidence of iron deficiency and anemia. For example, it is estimated that 40% to 55% of all home parenteral nutrition patients are iron deficient. We believe, based on our data with hemodialysis patients, FPC platformas a home infusion therapy for iron deficiency anemia may have distinct advantages over currently available iron replacement therapy options.
We plan on initiating a Phase 2 clinical study in home infusion patients with iron deficient anemia during the second half of 2021 to transformconfirm the dose and duration of FPC treatment. We expect data from the trial in the second half of 2022. Prior to commencing this study, the company is planning to further review and discuss this clinical plan with the FDA. After reviewing the development plan with the FDA, and subject to clarifying expected clinical development requirements, we expect to initiate the trial in the second half of 2021.
Pipeline Development
In our R&D pipeline, we are also exploring FPC’s impact in the treatment of iron deficiency and iron deficiency anemia in a wide variety of disease states across the globe while improving patients’ lives. Accordingly, as an initial step, we are building the foundation to become a leading medical and commercial organization in the field of dialysis.

Triferic 
Triferic is the Company’s first proprietary iron therapy from the FPC therapeutic platform that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. Triferic Dialysate was the first FDA approved product indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysishospitalized heart failure patients. On March 27, 2020, the FDA approved Triferic AVNU, a novel intravenous formulation of Triferic that would be used for the same indication. Descriptions of Triferic Dialysate and Triferic AVNU are set forth below.

TrifericDialysate
Triferic Dialysate, our dialysate formulation of Triferic, received FDA approval in 2015 and remains the first FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Triferic Dialysate received a reimbursement J-code on January 1, 2016 from the Centers for Medicare & Medicaid Services (the "CMS"), providing that Triferic Dialysate would be reimbursed for administration to dialysis patients within the existing fixed-price “bundle” of payments that CMS provides to dialysis providers.  On April 26, 2019, pursuant to a request we submitted earlier in 2019, we were notified of a preliminary recommendation by CMS to grant our powder packet formulation of Triferic Dialysate a separate J-Code, which became effective on July 1, 2019.
In June 2018, the Company determined, based on feedback provided from CMMI, that Triferic Dialysate was unlikely to obtain add-on reimbursement in the near term. As a result, the Company changed its commercialization strategy to plan for the commercial launch of Triferic Dialysate with reimbursement within the bundle of payments to dialysis providers, while continuing to develop Triferic AVNU (discussed below). We commercially launched Triferic Dialysate in May 2019.
Triferic AVNU (formerly I.V. Triferic)
We are also developing Triferic AVNU, an intravenous injection formulation of Triferic, for use by hemodialysis clinicsMore than one million people in the United States as well as international markets. On March 27, 2020, we received FDA approvalare hospitalized each year for Triferic AVNU, and we intend to initiate a sample evaluation program for Triferic AVNU during the third quarteracute heart failure. Clinical improvement in heart failure has already been demonstrated with older first-generation forms of 2020 with commercialization expected to followIV iron in clinical trials in the fourth quarter of 2020. Triferic AVNU will be reimbursed within the existing fixed-price bundle of paymentsoutpatient setting. We believe that CMS provides to dialysis providers.
While we intend to market and sell Triferic Dialysate and Triferic AVNU directly in the United States, our international strategy is to partner with and license these products to established companies in other regions of the world to assist in the further development (primarily clinical trials and regulatory activities), if necessary, and commercialize in those regions. We continue to pursue international licensing opportunities in a number of countries and specific regions.
Dialysis Concentrates
We manufacture, sell,FPC may deliver and distribute hemodialysis concentrates, along with a line of ancillary dialysis products abroad.  We use Baxter as our exclusive marketer and distributor in the United States and in select foreign markets.  Dialysate concentrates accounted for approximately 96% of our revenues for the year ended December 31, 2019, with ancillary products and Triferic accounting for most of the remainder.  We receive a pre-defined gross profit margin on our concentrate products sold pursuantrapidly bioavailable iron to the Baxter Agreement, subject to an annual true-up of costs.
Calcitriol (Active Vitamin D) Injection
Calcitriol, an active Vitamin D injection for the management of hypocalcemiaheart and improve cardiac energetics during hospitalization. This effect could help patients recover faster resulting in patients undergoing chronic hemodialysis, is FDA approved under an Abbreviated New Drug Application ("ANDA"). To date, we have not commercially launched Calcitriol. Followingimproved function, shorter hospital stays and fewer 30-day re-admissions. If so, these outcomes would translate into a strategic review of this product, including pricing, commercial distributionmeaningful reduction in healthcare costs and marketing, manufacturing efficiencies and capacity (including potential capital investment), we have determined commercialization of Calcitriol in the United States would not be viable at this time. The decision was based, in part, on the fact that prevailing market prices for similar Vitamin D products are lower than our cost to produce Calcitriol on a dose-equivalent basis, and as a result, it would be difficult for us to market Calcitriol profitably. As a result of this decision, we recorded an inventory reserve reflecting the remainder of our Calcitriol inventory. As of June 30, 2020, this reserve totaled $0.7 million. We are in the process of disposing of all inventory and in March 2020, we notified the FDA of our intention to withdraw the ANDA. On May 4, 2020, the ANDA was withdrawn.
Clinical Development
Although Triferic is approved for commercial sale in the United States, it is not approved for sale in other major markets globally.  We have received regulatory guidance from the European Medicines Agency ("EMA") regarding the clinical studies that are needed to file for approval of Triferic AVNU in Europe.  At the present time, we do not intend to commence these clinical studies, absent finding a development partner in Europe or raising additional capital. In conjunction with our licensee in China, Wanbang Biopharmaceutical, Co., Ltd. ("Wanbang"), we completed two clinical pharmacology studies in China during 2019.human suffering. We expect Wanbang to initiate an additional clinical study during 2020 that is required to support a submission for regulatory approval

in China. In addition, pursuant to the licensing agreement with Sun Pharmaceutical Industries Ltd. ("Sun Pharma"), our licensee in India, meetings between Sun Pharma and the regulatory authorities in India have been initiated. Sun Pharma continues to follow up with the Indian regulatory authorities to determine the requirements for approval of Triferic in India. See "Item 1A - Risk Factors" below for a discussion of the potential impact of COVID-19 on such clinical studies.
As a post-approval requirement under the Pediatric Research Equity Act, we are required to conduct a further clinical study of the effectiveness of Triferic in a pediatric patient population. We have reached agreementcommunicate with the FDA in 2021 regarding a development pathway for this indication.
We continue exploring other potential patient populations for application of our technology. We are considering disease states where patients can benefit the most from an effective treatment for iron deficiency, and EMA onwhere the design of this study. We have engaged a contract research organizationdevelopment path, cost estimates and reimbursement are in process of selecting sites in the United States and selected EU countries. We expect to initiate enrollment in the study during the third quarter of 2020. We expect that the data from this study could be used as part of the overall clinical data package to support approval by the EMA, if and when we are able to complete the other clinical trials needed to support making such a filing. See "Item 1A - Risk Factors" below for a discussion of the potential impact of COVID-19 on such clinical studies.most favorable.


27
Additionally, we plan to leverage our development and regulatory experience with Triferic and believe that our FPC technology has the potential to be developed for use in other indications, in which iron replacement is required. In addition, we are assessing potential investments to evaluate other product presentations of Triferic within ESKD.

Results of Operations for the three months endedThree Months Ended June 30, 20202021 and 20192020
The following table summarizes our operating results for the periods presented below (dollars in thousands):
For the Three Months Ended June 30,For the Three Months Ended June 30,
2020 % of Revenue 2019 % of Revenue % Change2021% of Revenue2020% of Revenue% Change
         
Net Sales$15,896
   $14,846
   7.1 %Net Sales$15,137 $15,896 (4.8)%
Cost of Sales15,015
 94.5 % 14,113
 95.1 % 6.4
Cost of Sales15,399 101.7 %15,015 94.5 %2.6 
Gross Profit881
 5.5
 733
 4.9
 20.1
Gross (Loss) ProfitGross (Loss) Profit(262)(1.7)881 5.5 (129.7)
         
Research and Product DevelopmentResearch and Product Development2,416 16.0 1,616 10.2 49.5 
Selling and Marketing1,997
 12.6
 2,219
 14.9
 (10.0)Selling and Marketing1,468 9.7 1,997 12.6 (26.5)
General and Administrative2,871
 18.1
 5,497
 37.0
 (47.8)General and Administrative3,677 24.3 2,871 18.1 28.1 
Settlement Expense, net of Reimbursement—
 —
 430
 2.9
 —
Research and Product Development1,616
 10.2
 2,958
 19.9
 (45.4)
Operating Loss$(5,603) (35.3)% $(10,371) (69.9)% (46.0)%Operating Loss$(7,823)(51.7)%$(5,603)(35.2)%39.6 %
Net Sales
During the three months ended June 30, 2020,2021, our net sales were $15.9$15.1 million compared to net sales of $14.8$15.9 million during the three months ended June 30, 2019.2020. The increasedecrease of $1.1$0.8 million was primarily due to increaseda decrease in sales in ourof dialysis concentrates products. Triferic Dialysate net sales for the three months ended June 30, 2020 included approximately $0.2 million of Triferic Dialysate product sales to United States customers. Triferic was launched in Q2 2019 via the sample evaluation program and there were nominal revenues for the same period in 2019.
Gross Profit
Cost of sales during the three months ended June 30, 20202021 was $15.4 million, resulting in gross loss of $0.3 million during the three months ended June 30, 2021, compared to cost of sales of a $15.0 million resulting inand a gross profit of $0.9 million during the three months ended June 30, 2020, compared to cost of sales of a $14.1 million and a gross profit of $0.7 million during the three months ended June 30, 2019.2020. Gross profit increaseddecreased by $0.2$1.2 million in the second quarter of 2020 compared to the second quarter of 2019, due primarily to the increase in sales of $1.0 million; offset by an increase in labor and material costs $0.8 million to address requirements to support demand arising from the ongoing COVID-19 pandemic. Gross profits are primarily related to our concentrates business at this time. The Company anticipates that potential future sales of Triferic will impact the mix on our future gross profits.
Selling and Marketing Expense

Selling and marketing expenses were $2.0 million during the three months ended June 30, 2020, compared with $2.2 million during the three months ended June 30, 2019. The decrease of $0.2 million is primarilymainly due to a decrease in marketing costs associated with the initial investment in a specialty commercial teamconcentrate sales and marketing programs to support the launch of Triferic in Q2 2019.
General and Administrative Expense
General and administrative expenses were $2.9 million during the three months ended June 30, 2020, compared with $5.5 million during the three months ended June 30, 2019. The decrease of $2.6 million is due primarily to a decrease in stock compensation of $2.0 million, relating to a decrease in incentive compensation from forfeited equity awards associated with the departure of our former President and Chief Executive Officer in April 2020; a decrease in legal expense of $0.7 million, relating to previous litigation that has since been resolved; partially offset by an increase of $1.2 million for severance payin costs related to protocols implemented because of the same former Presidentongoing COVID-19 pandemic, shipping, fuel and Chief Executive Officer.labor.
Research and Product Development Expense
Research and product development expenses were $1.6$2.4 million for the three months ended June 30, 2020,2021, compared with $3.0$1.6 million during the three months ended June 30, 2019.2020. The decreaseincrease of $1.4$0.8 million was primarily due primarily to the payment for the Triferic AVNU NDA application fee of $1.3 million in Q2 2019. The Company is continuing to invest in its medical and scientific programs to support the global launch of Triferic and thecontinued advancement of our FPC technology platform.
Selling and Marketing Expense
Selling and marketing expenses were $1.5 million during the three months ended June 30, 2021, compared with $2.0 million during the three months ended June 30, 2020. The decrease of $0.5 million is primarily due to a decrease in marketing costs related to Triferic (dialysate) partially offset by a slight increase in costs associated with the launch of Triferic AVNU.
General and Administrative Expense
General and administrative expenses were $3.7 million during the three months ended June 30, 2021, compared with $2.9 million during the three months ended June 30, 2020. The increase of $0.8 million is due primarily to an increase in stock compensation of $1.9 million, which was a decrease in incentive compensation in Q2 2020 of $1.5 million from forfeited equity awards of the former President and Chief Executive Officer; partially offset by a decrease of $0.8 million for the reduction of severance costs related to our former President and Chief Executive Officer.
Other Income (Expense)
Other income for the three months ended June 30, 20202021 was $68,815,$7,000, consisting primarily of interest income of $66,750 and $2,065 of realized gains on investments.income. Other income for the three months ended June 30, 20192020 was $78,611,$0.1 million, consisting of $74,476primarily of interest income and $4,135income. Other expense for the three months ended June 30, 2021 was $0.6 million of realized gainsinterest expense related to our debt facility (see Note 15 for more
28

information on investments.our debt facility). Other expense for the three months ended June 30, 2020 was $1.4 million, consisting of interest expense of $0.5 million related to our debt facility (see Note 15 for more information on our debt facility) and warrant modification expense of $0.8 million. No interest expense was recorded for the three months ended June 30, 2019.

Results of Operations for the six months endedSix Months Ended June 30, 20202021 and 20192020
The following table summarizes our operating results for the periods presented below (dollars in thousands):
 For the Six Months Ended June 30,
 2020 % of Revenue 2019 % of Revenue % Change
          
Net Sales$31,753
   $30,405
   4.4 %
Cost of Sales29,759
 93.7 % 28,662
 94.3 % 3.8
Gross Profit1,994
 6.3
 1,744
 5.7
 14.4
          
Selling and Marketing4,069
 12.8
 5,321
 17.5
 (23.5)
General and Administrative8,144
 25.6
 11,717
 38.5
 (30.5)
Settlement Expense, net of Reimbursement—
 —
 430
 1.4
 (100.0)
Research and Product Development3,438
 10.8
 3,456
 11.4
 (0.5)
Operating Loss$(13,657) (43.0)% $(19,181) (63.1)% (28.8)%

For the Six Months Ended June 30,
2021% of Revenue2020% of Revenue% Change
Net Sales$30,611 $31,753 (3.6)%
Cost of Sales30,471 99.5 %29,759 93.7 %2.4 
Gross Profit140 0.5 1,994 6.3 (93.0)
Research and Product Development4,224 13.8 3,438 10.8 22.9 
Selling and Marketing3,319 10.8 4,069 12.8 (18.4)
General and Administrative7,602 24.8 8,145 25.7 (6.7)
Operating Loss$(15,005)(49.0)%$(13,658)(43.0)%9.9 %
Net Sales

During the six months ended June 30, 2020,2021, our net sales were $31.8$30.6 million compared to net sales of $30.4$31.8 million during the six months ended June 30, 2019.2020. The increasedecrease of $1.4$1.2 million was primarily due to higher domestic dialysis concentratea decrease in sales of $1.0 million and an increase in Triferic Dialysate sales of approximately $0.4 million compared to the six months ended June 30, 2019. Triferic was launched in the second quarter of 2019 via the sample evaluation program and there were nominal revenues for the same period in 2019.

dialysis concentrates products.
Gross Profit (Loss)

Cost of sales during the six months ended June 30, 20202021 was $30.5 million, resulting in gross profit of $0.1 million during the six months ended June 30, 2021, compared to cost of sales of a $29.8 million resulting inand a gross profit of $2.0 million during the six months ended June 30, 2020,2020. Gross profit decreased by $1.9 million mainly due to a decrease in concentrate sales and an increase in costs related to protocols implemented because of the ongoing COVID-19 pandemic, shipping and fuel costs and labor.
Research and Product Development Expense
Research and product development expenses were $4.2 million for the six months ended June 30, 2021, compared to cost of sales of $28.7 million and a gross profit of $1.7with $3.4 million during the six months ended June 30, 2019. Gross profit increased by $0.32020. This increase of $0.8 million is primarily due to continued investments the Company is making in its medical and scientific programs to support the continued advancement of our FPC technology platform.
Selling and Marketing Expense
Selling and marketing expenses were $3.3 million during the six months ended June 30, 20202021, compared to the six months ended June 30, 2019. The increase was due primarily to a gross margin increase of $0.3 million in our Triferic Dialysate product in 2020. In comparison, the launch and sales of Triferic Dialysate occurred in the second quarter of 2019 and had no to minimal impact during the six months ended June 30, 2019. Gross profits are primarily related to our concentrates business at this time. The Company anticipates that potential future sales of Triferic will impact the mix on our future gross profits.
Selling and Marketing Expense
Selling and marketing expenses werewith $4.1 million during the six months ended June 30, 2020, compared2020. The decrease of $0.8 million is primarily due to a decrease in marketing costs related to Triferic (dialysate) partially offset by a slight increase in costs associated with $5.3the launch of Triferic AVNU.
General and Administrative Expense
General and administrative expenses were $7.6 million during the six months ended June 30, 2019. The decrease of $1.2 million is due primarily to the decrease in marketing costs of $2.0 million, partially offset by an increase in costs associated2021, compared with hiring, training and educating new employees of $0.8 million. The fluctuation in these costs are mainly due to the timing of the Triferic Dialysate launch in the second quarter of 2019. We expect those costs to level off quarter over quarter going forward.
General and Administrative Expense
General and administrative expenses were $8.1 million during the six months ended June 30, 2020, compared with $11.72020. The decrease of $0.5 million duringis due primarily to a decrease of $0.8 million from the six months ended June 30, 2019. The $3.6 million decrease was driven primarily by decreasescompletion of severance pay related to stock compensation, legal, recruiting and consulting fees, partially offset by an increase in labor costs. The increase in labor costs and decrease in stock compensation primarily relate to the resignation of our former President and Chief Executive Officer (CEO); a decrease in April 2020.  
Researchlegal costs of $0.3 million, relating to previous litigation that has since been resolved; and Product Development Expense
Researcha decrease in insurance and product development expenses was $3.4accounting costs of $0.2 million, relating to reduced premiums; partially offset by an increase of $0.7 million for both the six months ended June 30,stock compensation, relating to a decrease in Q2 2020 incentive compensation from forfeited equity awards related to our former President and 2019. Research and development expensesCEO.
29

Other Income (Expense)
Other income for the six months ended June 30, 2020 included clinical trials and other product development expenses2021 was $18,000, consisting primarily of $1.2 million for Triferic, compared to $0.7 million during the six months ended June 30, 2019. The Company is continuing to invest in its medical and scientific programs to support the global launch of Triferic and the advancement of our FPC technology platform.
Settlement Expense, net of Reimbursement
Settlement expense was nil for the six months ended June 30, 2020, compared to $0.4 million in for the six months ended June 30, 2019. Settlement expense for the six months ended June 30, 2019 reflected the terms of the confidential settlement agreement and mutual release entered into in August 2018 relating to the Company’s former Chief Executive Officer, Robert Chioini, former Chief Financial Officer, Thomas Klema, and a former and then current director. 

Other Income (Expense)
interest income. Other income for the six months ended June 30, 2020 was $241,821,$0.2 million, consisting primarily of interest income of $237,827 and $3,994 of realized gains on investments.income. Other incomeexpense for the six months ended June 30, 20192021 was $210,025, consisting of $192,002$1.2 million of interest income and $18,023 of realized gainsexpense related to our debt facility (see Note 15 for more information on investments.our debt facility). Other expense for the six months ended June 30, 2020 was $1.5 million, consisting of warrant modification expense of $0.8 million and interest expense of $0.6 million related to our debt facility (see Note 15 for more information on our debt facility). No interest expense was recorded for the six months ended June 30, 2019.facility.
30

Liquidity and Capital Resources
Since inception, Rockwell has incurred significant net losses and has funded its operations primarily through revenue from commercial products, proceeds from the issuance of debt and equity securities and payments from partnerships. At June 30, 2021, Rockwell had an accumulated deficit of approximately $353.6 million and stockholders' equity of $18.2 million. As of June 30, 2020, we2021, Rockwell had approximately $40.0$41.0 million of cash, cash equivalents and investments available-for-sale, and working capital of $40.0$18.4 million. Net cash used in operating activities for the six months ended June 30, 20202021 was approximately $16.2$17.4 million.
On March 22, 2019, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock through the Agent up to $40.0 million. As of December 31, 2019, the Company sold 1,840,443 shares of its common stock pursuant to the Sales Agreement for gross proceeds of approximately $5.4 million, at a weighted average selling price of approximately $2.92. The Company paid approximately $0.3 million in commissions and offering fees related to the sale of the common stock.
During the six months ended June 30, 2020, the Company sold 987,716 of shares of its common stock pursuant to the Sales Agreement with the Agent for proceeds of $2.0 million, net of issuance costs. As of June 30, 2020, approximately $32.6 million remains available for sale under this facility.
On February 4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald & Co., as underwriter, pursuant to which the Company agreed to issue and sell up to 3,670,212 shares of its common stock, which included 478,723 shares optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the “Offering”). On February 19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering. The Offering was made pursuant to the Company’s effective Registration Statement on Form S-3 (File No. 333-227363), which was previously filed with the SEC.
On March 16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”), as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the “Term Loans”). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the FDA approval of the Company’s New Drug Application for Triferic AVNU. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.
The Company is entitledsubject to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025covenants and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00%, with an initial interest rate of 8.75% per annum. The Company has the option,cure provisions under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. For the six months ended June 30, 2020 and 2019, interest expense amounted to $0.6 million.
Theits Loan Agreement is secured by all assetswith Innovatus. As of the Company and Rockwell Transportation, Inc. Proceeds will be used for working capital purposes. The Loan Agreement contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months salesdate of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 ifthis report, the Company draws the second tranche of $5.0 million. As of June 30, 2020, we wereis in compliance with all covenants. As a result of the reportingongoing COVID-19 pandemic and its effect on the Company's sales activities, among other factors, the Company may not be able to satisfy such covenants over the next 12 months. However, based on the foregoing, the Company has classified amounts payable under the Loan Agreement as a current liability. If and when the Company reaches an agreement with Innovatus to avoid an event of default, the amounts payable under the Loan Agreement will be reclassified. The financial statements for June 30, 2021, have been prepared with the assumption that the Company will be able to agree to an appropriate remedy during the applicable cure period for any future breaches of operating covenants. However, ifIf the Company is unable to maintain compliancecomply with the reporting and financial covenants in the future, the Company could experience an event of default under the Loan Agreement, whichit would negatively impact the Company’s liquidity. For more information, see the risk factor entitled “Our Loan Agreement with Innovatus contains certain covenants that could adversely affect our operations and, if an event of default werepursue all available cure options in order to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation. The occurrence of any of these events could cause a significant adverse impact on our business, prospects and share price.” in “Item 1A-Risk Factors.”regain compliance (See Note 15 for further detail).

Based on the capital raise and debt financing noted above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

The Company expects it will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term businessstrategic plan, including the commercial launch and medical education programscommercialization of Triferic Dialysate(dialysate) and Triferic AVNU in dialysis, generating additional data for Triferic in dialysis, developing FPC for iron deficiency anemia in patients undergoing home infusion and the furtherfor progressing our pipeline development program of ournew indications for its FPC pipeline programs.platform. If the Company is unable to generate sufficient revenue from sales of its existing long-term business plan,commercial products and from partnerships, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.

Based on the currently available working capital and managements assumption that the Company will be able to agree to an appropriate remedy, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.

General
The actual amount of cash that we will need to execute our business strategy is subject to many factors, including, but not limited to, the expenses and revenue associated with the commercial launch of Triferic Dialysateoperations in the United States and Triferic AVNU;internationally (with partners); the timing and magnitude of cash received from drug product sales; and the timing and expenditures associated with the development of Triferic for international markets; the timing and expenditures associated with the development of further innovative administration techniques of Triferic for dialysis patients; the timing and expenditures associated with the development ofprograms including our FPC technology for patients with iron-deficiency anemia in other disease states;home infusion and potentially acute heart failure; the costs associated with ongoing litigationour manufacturing and investigatory matters. transportation operations related to our concentrate business; any potential accelerated amortization under the Loan Agreement in the event of a failure to satisfy operating covenants..
We may elect to raise capital in the future through one or more of the following: (i) equity and debt raises through the equity and capital markets, though there can be no assurance that we will be able to secure additional capital or funding on acceptable terms, ofor if at all; and (ii) strategic transactions, including potential alliances and collaborations focused on markets outside the U.S.,United States, as well as potential combinations (including by merger or acquisition) or other corporate transactions. In particular, our Baxter Agreement prohibits us from entering into a contract that would encumber the assets used in our concentrate business without the prior written consent of Baxter. Due to the fact that the assets used in our concentrate business currently constitute a substantial portion of the tangible assets we own other than our drug inventory, we may not be able to, or we may find it difficult, to obtain secured debt financing without the consent of Baxter.
We believe that our ability to fund our activities in the long term will be highly dependent upon 1) our ability to successfully launchexecute on the development of the FPC platform for new therapies, and 2) our ability to commercialize and increase adaptation of Triferic Dialysate(dialysate) and Triferic AVNU. Our commercializationBoth of Triferic Dialysate and Triferic AVNUthese strategies is subject to significant risks and uncertainties including riskssuch that there can be no assurance that we will be successful is achieving approval of FPC in the commercialization ofa new therapeutic area or that we will be able to have sustained commercial success with Triferic in accordance with(dialysate) and Triferic AVNU. If our plans. Ifplanned clinical program is delayed or fails or if our commercialization of Triferic Dialysate(dialysate) and/or Triferic AVNU should be delayed for any reason or not proceed in accordance with our plans,fail to increase sales, we may be forced to implement cost-saving measures that may potentially have a negative impact on our activities and potentially the results of our research and development programs. If our launchEven though we began commercialization of Triferic Dialysate and/or(dialysate) and Triferic AVNU is unsuccessful or our commercial launch does not proceed as planned, if the results are unsuccessful, we may be unable to secure the additional capital that we will require to continue our
31

research and development activities and operations, which could have a material adverse effect on our business. If we are unable to raise the required capital, we may be requiredforced to curtail all of our activities and, ultimately, cease operations. Even if we are able to raise sufficient capital, such financings may only be available on unattractive terms, or result in significant dilution of stockholders’ interests and, in such event, the market price of our common stock may decline.
Cash Used in Operating Activities
Net cash used in operating activities was $17.4 million for the six months ended June 30, 2021 compared to net cash used in operating activities of $16.2 million for the six months ended June 30, 2020. The net loss for thisincrease in cash used from operating activities during the current period was lower thanprimarily due to changes in current balance sheet accounts in the ordinary course of business of approximately $3.0 million, including an increase in net cash used in operating activities by $1.3accounts receivable of $1.2 million which was primarily attributable to non-cash expenses of $1.6 million, consisting primarily of $0.8 million of warrant modification expense, $0.7 million of amortization of the right to use assets, $0.4 million of depreciation and amortization, ($0.5) million of stock-based compensation and a ($2.9) million net changereduction in assetsaccounts payable and liabilities. 
Netaccrued expense of approximately $0.4 million. Overall, our cash used in operating activities was $15.8 millionburn for the six months ended June 30, 2019. The net loss for this period2021 was higherin line with our expectations, and we continue to expect, in aggregate, 2021 cash burn to be lower than net2020 cash used in operating activities by $3.2 million, which was primarily attributable to non-cash expenses of $4.5 million, consisting of $3.0 million of stock-based compensation, $1.0 million of amortization of the right to use assets, $0.4 million of depreciation and amortization, and a ($1.4) million net change in assets and liabilities.burn.
Cash Provided by (Used In) Investing Activities
Net cash provided by investing activities was $1.1 million during the six months ended June 30, 2021 compared to net cash provided by investing activities of $0.7 million duringfor the six months ended June 30, 2020. The net cash provided was primarily due to the sales of our available-for-sale investments of $17.5 million, offset by $16.5 million used for the purchase of investments available-for-sale and $0.3 million for the purchase of equipment.
Net used in investing activities was $3.8 million during the six months ended June 30, 2019. The cash used2021 was primarily due to thesales and purchase of our available-for-sale investments of $21.8 million, offset by $18.8 million provided byduring the sale of investments

available-for-sale, $0.5 million for the purchase of research and development licenses acquired from a related party and $0.3 million for the purchase of equipment.quarter.
Cash (Used in) Provided by Financing Activities
Net cash used in financing activities was $6,000 during the six months ended June 30, 2021 compared to the net cash provided by financing activities wasof $30.4 million duringfor the six months ended June 30, 2020. The net cash provided during the six months ended June 30, 2020 was primarily due to net proceeds of $21.2 million related to proceeds from the Loan Agreementdebt facility and $8.0 million and $2.0 million from the sale of our common stock, related to our public offering, and our at-the market offering, respectively.
Net cash providedoffset by financing activities was $18.3$0.8 million during the six months ended June 30, 2019. The net cash provided was primarily due to net proceeds of $16.1 million and $2.1 million from the sale of our common stock, related to our public offering and our at-the market offering, respectively.for payments on short term notes.
COVID-19 Impact

The COVID-19 pandemic and resulting global disruptions have adversely affected our business and operations, including, but not limited to, our sales and marketing efforts and our research and development activities, and the operations of third parties upon whom we rely. As noted above, we intend to initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch. Quarantines, shelter-in-place, executive and similar government orders may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending onThe Company's international business development activities may also continue to be negatively impacted by COVID-19, especially with the severity of the impact on our salesrecent surge in infections internationally, ongoing international travel restrictions and marketing efforts, the timing of our commercial launch of Triferic AVNU could be adjusted into the first quarter of 2021.quarantines or shelter-in-place orders.

The COVID-19 pandemic and resulting global disruptions have caused significant volatility in financial and credit markets. We have utilized a range of financing methods to fund our operations in the past; however, current conditions in the financial and credit markets may limit the availability of funding or increase the cost of funding. Due to the rapidly evolving nature of the global situation, it is not possible to predict the extent to which these conditions could adversely affect our liquidity and capital resources in the future.
Critical Accounting Policies and Significant Judgments and Estimates
Our critical accounting policies and significant estimates are detailed in our Annual Report on Form 10-K for the year ended December 31, 2019.2020. Our critical accounting policies and significant estimates have not changed from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, except for those subjects mentioned in the section of the notes to the condensed consolidated financial statements titled Adoption of Recent Accounting Pronouncements.2020.
Recently issued and adopted accounting pronouncements:
We have evaluated all recently issued accounting pronouncements and believe such pronouncements do not have a material effect our financial statements. See Note 3 of the condensed consolidated financial statements at June 30, 2020.2021.
32
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

Item 3.  Quantitative and Qualitative Disclosures about Market Risk

Per §229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in §229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item.
Item 4.  Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure material information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Controller and Principal AccountingChief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management necessarily was required to apply its judgment in evaluating the cost‑benefit relationship of possible controls and procedures.

Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Controller and Principal AccountingChief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2020.2021. Based upon that evaluation, our Chief Executive Officer and Controller and Principal AccountingChief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2020.
The material weaknesses related to change management and third-party management controls in our Information Technology General Controls ("ITGC") which had a pervasive impact on other ITGC dependent business activity level controls in our internal controls over financial reporting, described in our Annual Report on Form 10-K for the year ended December 31, 2019, has been remediated. The Company is still evaluating the design, implementation and operating effectiveness of ITGC user access security, segregation of duties as it relates to user access controls and the pervasive effect on other ITGC dependent business activity level internal control cycles. Notwithstanding the material weaknesses, the Company’s management, including the Chief Executive Officer and Controller and Principal Accounting Officer, have concluded that the condensed consolidated financial statements as of June 30, 2020, are fairly stated, in all material respects, in accordance with generally accepted accounting principles in the United States for each of the periods presented herein.
In connection with the user access security, segregation of duties as it relates to user access controls and the pervasive effect of the ITGC material weaknesses, management has taken a number of steps with the intention of remediating the above control deficiencies. We continue to implement enhanced procedures and controls to remediate our material weaknesses in internal control over financial reporting. 2021.
Changes in Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. We maintainThere were no changes in our internal control over financial reporting designed to provide reasonable, but not absolute, assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. 
We continue to make further improvements to our internal controls over financial reporting, in addition to the improvements developed in 2019. During the quarter ended June 30, 2020, we implemented the following:
Remediated the ITGC control deficiencies in connection with change management and third-party management controls.
Implemented and started our 2020 audit program, utilizing a National Audit firm as our internal audit partner, which includes in-house remediation testing of our user access security, segregation of duties as it relates to user access controls and other ITGC dependent business activity level internal control cycles.
Enhanced evidentiary review and documentation of key ITGC controls and implemented new programs and policies to provide improved control over change management and third-party management controls to the ERP system.
The remediationevaluation required by Rule 13a-15(d) of the material weaknesses is amongExchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our highest priorities. Our Audit Committee continually assesses the progress and sufficiency of these initiatives and make adjustments as and when necessary. As of the date of this report, our management believes that our efforts, when completed, will remediate the material weaknesses in internal control over financial reporting. However, there can be no assurance that our efforts will result in remediation of the material weaknesses in internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1.  Legal Proceedings
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)


The disclosure set forth above in Note 14  (Commitments and Contingencies – Litigation) to our unaudited condensed consolidated financial statements is incorporated herein by reference.
Additionally, we aremay be involved in certain otherroutine legal proceedings from time to time before various courts and governmental agencies. We cannot predict the final disposition of such proceedings. We regularly review legal matters and record provisions for claims that are considered probable of loss. The resolution of these pending proceedings is not expected to have a material effect on our operations or consolidated financial statements in the period in which they are resolved.
Item 1A. Risk Factors
Other than those set forth below, thereThere have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 20192020 under “Item 1A — Risk Factors”.Factors.”
We have limited capital resources and will likely need additional funding before we are able to achieve profitability. If we are unable to raise additional capital on attractive terms, or at all, we may be unable to sustain our operations.
We have limited capital resources, a cumulative deficit of approximately $321.4 million since inception and expect to incur further losses for the foreseeable future.  As of June 30, 2020, we had approximately $40.0 million of cash, cash equivalents and investments available-for-sale, and working capital of $40.0 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $16.2 million.
On March 22, 2019, the Company entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), pursuant to which the Company may offer and sell from time to time up to $40.0 million of shares of the Company’s common stock through the Agent. As of December 31, 2019, the Company sold 1,840,443 shares of its common stock pursuant to the Sales Agreement for gross proceeds of $5.4 million, at a weighted average selling price of approximately $2.92. The Company paid $0.3 million in commissions and offering fees related to the sales. During the six months ended June 30, 2020, the Company sold 987,716 of shares of its common stock pursuant to the Sales Agreement with the Agent for proceeds of $2.0 million, net of issuance costs. As of June 30, 2020, approximately $32.6 million remains available for sale under this facility.
On February 4, 2020, the Company entered into an underwriting agreement with Cantor Fitzgerald & Co., as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of up to 3,670,212 shares of its common stock, which included 478,723 optional shares that may be sold pursuant to an over-allotment option granted to the underwriters. On February 6, 2020, the Company closed the sale of 3,191,489 shares of its common stock at the public offering price of $2.22 per share (the “Offering”). On February 19, 2020, the underwriter exercised its over-allotment option to purchase an additional 478,723 shares at a price of $2.22 per share, which closed on February 21, 2020. The Company raised a total of $8.0 million, net of issuance costs of $0.1 million, relating to the sale of the common stock in the Offering.
On March 16, 2020, Rockwell Medical, Inc. and Rockwell Transportation, Inc., as Borrowers, entered into a Loan and Security Agreement (the "Loan Agreement") with Innovatus Life Sciences Lending Fund I, LP, as collateral agent and the lenders party thereto, pursuant to which Innovatus, as a lender, agreed to make certain term loans to the Company in the aggregate principal amount of up to $35.0 million (the "Term Loans"). Funding of the first $22.5 million tranche was completed on March 16, 2020. The Company will be eligible to draw on a second tranche of $5.0 million upon achievement of certain milestones, including the FDA approval of the Company’s New Drug Application for Triferic AVNU. The Company will be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds. Net draw down proceeds were $21.2 million with closing costs of $1.3 million.
The Company is entitled to make interest-only payments for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans will mature on March 16, 2025, and will bear interest at the greater of (i) Prime Rate (as defined in the Loan Agreement) and (ii) 4.75%, plus 4.00% with an initial interest rate of 8.75% per annum. The Company has the option, under certain circumstances, to add 1.00% of such interest rate amount to the then outstanding principal balance in lieu of paying such amount in cash. The Loan Agreement is secured by all assets of the Company and Rockwell Transportation, Inc. and contains customary representations and warranties and covenants, subject to customary carve outs, and includes financial covenants related to liquidity and trailing twelve months sales of Triferic, with the latter beginning with the period ending December 31, 2020, or September 30, 2020 if the Company draws the second tranche of $5.0 million.

Based on the equity offerings and the Loan Agreement described above, management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report.
The Company will require additional capital to sustain its operations and make the investments it needs to execute upon its longer-term business plan, including the launch of Triferic Dialysate and Triferic AVNU. If the Company is unable to generate sufficient revenue from its existing long-term business plan, the Company will need to obtain additional equity or debt financing. If the Company attempts to obtain additional debt or equity financing, the Company cannot assume that such financing will be available on favorable terms, if at all.
Our near-term success depends substantially on the commercialization of Triferic Dialysate and Triferic AVNU. Although Triferic Dialysate and Triferic AVNU have been approved by the FDA, we may not be able to commercialize either product successfully.

Triferic Dialysate launched commercially in the United States in May 2019 and Triferic AVNU was approved by the FDA in March 2020; however, it is possible that either version of Triferic will not gain market acceptance and that we will not be successful in the commercialization of these products. We do not know whether we will be able to successfully implement our commercialization strategy for Triferic Dialysate and Triferic AVNU or whether our new business strategy will ultimately be successful.
Both formulations of Triferic will be reimbursed “within the bundle,” which means that dialysis providers will not receive any additional amount of reimbursement from Medicare or Medicaid to compensate them for the cost of purchasing and administering Triferic. This reimbursement status may result in a slower rate of commercial adoption, as we must work to show dialysis providers that improved patient outcomes, the reduction of utilization in other therapies and the resulting savings offset the costs associated with Triferic. Additionally, Triferic competes against current anemia therapies (including intravenous iron and the ESA class of drugs) and possibly other future products. Additionally, it may be difficult to gain market acceptance from dialysis chains, anemia managers and nephrologists and such acceptance may be slower than expected, if at all.
Market acceptance will depend on a number of factors, such as demonstration of Triferic Dialysate’s safety and efficacy, cost-effectiveness, and advantages over existing products. Other factors that may impact the commercial success and ultimate profitability of Triferic include:
the rate of adoption of Triferic Dialysate and Triferic AVNU relative to the shelf life of the existing inventory that we have on hand and whether we can sell our existing inventory before it expires;
our ability to manage inventory available for commercial sale;
the effectiveness of our marketing, sales and distribution strategies and operations for development and commercialization;
the impact of Triferic Dialysate and Triferic AVNU on established customer protocols, formularies and operational practices;
The ability and willingness of dialysis centers to adopt their protocols and utilize the drugs in a manner consistent with state regulatory agencies.
reimbursement of either formulation of Triferic by government and commercial payors;
our ability to execute our marketing strategy without significant additional expenditures;
our competitors’ activities, including aggressive marketing and pricing practices and other tactics to retain their market share;

our ability to successfully assert our patents against potential competitors who may seek to introduce generic versions of either formulation of Triferic;
our ability to comply with ongoing regulatory requirements applicable to either formulation of Triferic and the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping applicable to Triferic;
the impact of certain royalties related to our sale of either formulation of Triferic paid by us based on the profitability of either formulation of Triferic;
our ability to avoid third party patent interference or patent infringement claims;
our ability to maintain a continued acceptable safety profile of either formulation of Triferic;
the discovery of previously unknown problems with either formulation of Triferic or with any third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements; and
the ability to successfully manufacture enough commercial product and successfully complete our commercialization planning to enable a launch of Triferic AVNU in 2020.
An adverse development with respect to any of the foregoing may have a material adverse effect on our ability to manufacture and market either formulation of Triferic. We cannot assure you that we will be able to generate meaningful and sustained revenues through the sale of either formulation of Triferic. If we are not successful in commercializing either formulation of Triferic, or are significantly delayed in doing so, our entire investment in Triferic may be of no value, our inventory of finished product may expire or become obsolete (resulting in write-offs of such inventory), our licensing rights could be materially adversely affected and the price of our common stock could substantially decline. Even if we are successful in commercializing either formulation of Triferic, since the market is highly concentrated with two significant suppliers, our continued success may depend on adoption of Triferic Dialysate by the limited number of existing dialysis providers.
The ongoing COVID-19 pandemic may result in significant disruptions to our business operations, including the commercial launch of our Triferic products and our clinical trials, which could have a material adverse effect on our business.
Our business and its operations, including but not limited to our sales and marketing efforts and our research and development activities, could be adversely affected by health epidemics in regions where we have business operations, and such health epidemics could cause significant disruption in the operations of third parties upon whom we rely. In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to other countries, including the United States, and has been declared a pandemic by the World Health Organization. In response to public health directives and orders related to COVID-19, we have implemented work-from-home policies for substantially all employees, excluding our essential manufacturing and distribution employees. The effects of executive and similar government orders, shelter-in-place orders and our work-from-home policies may negatively impact our growth and productivity, disrupt our business, including our sales and marketing activities, and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.
Quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, may impact personnel at our manufacturing facilities and third-party manufacturing facilities in the United States, Europe and other countries, or the availability or cost of materials we use or require to conduct our business, including product development, which would disrupt our supply chain. If the COVID-19 pandemic were to negatively affect our manufacturing facilities, the costs related to such manufacturing may increase and the productivity of our facilities may decrease. Furthermore, some of our manufacturers and suppliers are in Europe and may be impacted by port closures and other restrictions resulting from the COVID-19 pandemic, which may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.

We commercially launched Triferic Dialysate in the United States in May 2019 and we intend to initiate a sample evaluation program for Triferic AVNU during the third quarter of 2020 in order to prepare for a commercial launch. Quarantines, shelter-in-place, executive and similar government orders, or changes in prospective customer practices in response to the COVID-19 outbreak, may negatively impact our sales and marketing activities, particularly if our sales representatives are unable to interact with current and potential customers to the same extent as before onset of the COVID-19 pandemic. Depending on the severity of the impact on our sales and marketing efforts, the commercial launch of Triferic AVNU could be delayed.
In addition, we may face decreased demand if our dialysis patients are unable to travel to dialysis clinics or if dialysis clinics are unable to make additional protocol changes that are required for Triferic. In order to ensure the safety of patients and staff at the dialysis clinics that use our Triferic products, we expect the dialysis clinics will implement a number of changes to their safety procedures. In addition, the dialysis clinics may face challenges related to decreased staffing, if staff members are affected by COVID-19. Changes to safety procedures and/or staffing issues may impede the clinics’ ability to make additional protocol changes that are required for Triferic.
In addition, our clinical trials and our partners’ clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, Wanbang is our commercialization partner for both Triferic Dialysate and Triferic AVNU in China and we currently expect Wanbang to initiate additional clinical studies during 2020 that are necessary to support a submission for regulatory approval in China. Such clinical studies may be delayed to later in 2020 than previously expected. In addition, meetings between Sun Pharma and the regulatory authorities in India related to our Triferic products have been postponed due to government restrictions in India. If COVID-19 continues to spread in the United States and elsewhere, we or our partners may experience additional disruptions that could severely impact our business and clinical trials, including:
delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;
delays in receiving legalization documents from foreign embassies, which are required to allow our partners to direct activities on behalf of the Company in local markets;
delays or difficulties in enrolling patients in our clinical trials;
delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials;
changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption of key clinical trial activities, such as clinical trial site monitoring and data entry and verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the completeness and integrity of clinical trial data and, as a result, determine the outcomes of the trial;
risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;
risk that participants enrolled in our clinical trials will not be able to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from COVID-19;
risk that participants enrolled in our clinical trials will not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services;

interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities;
delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;
limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
refusal of the FDA to accept data from clinical trials in affected geographies; and
interruption or delays to our clinical activities.
The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially affect our business and the value of our common stock.
The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. However, any one or a combination of these events could have an adverse effect on the operation of and results from our clinical trials and on our other business operations, which could negatively impact our business, operating results and financial condition.
The risks related to the ongoing COVID-19 pandemic may amplify the other risk factors described in this “Item 1A.-Risk Factors” and in the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019.
Our Loan Agreement with Innovatus contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay the outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation. The occurrence of any of these events could cause a significant adverse impact on our business, prospects and share price.
Pursuant to the Loan Agreement, we have pledged substantially all of our assets and the assets of our subsidiary, Rockwell Transportation, Inc., and have agreed that we may not sell or assign rights to our patents and other intellectual property without the prior consent of Innovatus. Additionally, the Loan Agreement contains affirmative, including financial covenants related to liquidity and trailing twelve months sales of Triferic, and negative covenants that, among other things, restrict our ability to:
incur additional indebtedness;
grant liens;
make distributions, including dividends;
enter into a merger or consolidation;
alter the business of the Company; or
sell all or a portion of the Company’s property, business or assets.
These terms of the Loan Agreement could prevent us from taking certain actions without the consent of our lenders, which may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our stockholders, placing us at a competitive disadvantage compared to our competitors who have less leverage and who therefore may be able to take advantage of opportunities that our leverage prevents us from exploiting. Our ability to comply with these covenants may be adversely affected by events beyond our control, and we cannot assure you that we can maintain compliance

with these covenants, which may result in an event of default. These covenants could limit our ability to make needed capital expenditures or otherwise conduct necessary or desirable business activities.
The Loan Agreement also includes customary events of default, including, among other things, a change of control or a failure to comply with certain of the covenants in the Loan Agreement. Upon the occurrence and continuation of an event of default, all amounts due under the Loan Agreement become (in the case of a bankruptcy event), or may become (in the case of all other events of default and at the option of Innovatus), immediately due and payable.
If an event of default under the Loan Agreement should occur, we could be required to immediately repay the outstanding indebtedness. If we are unable to repay this debt, the lenders would be able to foreclose on the secured collateral, including our cash accounts, and take other remedies permitted under the Loan Agreement. Even if we are able to repay the indebtedness on an event of default, the repayment of these sums may significantly reduce our working capital and impair our ability to operate as planned. The occurrence of any of these events could cause a significant adverse impact on our business and financial condition.
We do not anticipate paying dividends in the foreseeable future.
Since inception, we have not paid any cash dividends on our common stock and do not anticipate paying such dividends in the foreseeable future. In addition, the terms of our Loan Agreement with Innovatus restrict our ability to pay dividends to limited circumstances. As a result, investors in our common stock may only receive a return if the market price of our common stock increases.
The payment of dividends is within the discretion of our Board of Directors, subject to the restrictions in the Loan Agreement, and depends upon our earnings, capital requirements, financial condition and requirements, future prospects, restrictions in future financing agreements, business conditions and other factors deemed relevant by the Board. We intend to retain earnings and any cash resources to finance our operations. Therefore, it is highly unlikely we will pay cash dividends.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
33
ROCKWELL MEDICAL, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)

None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No.Description
10.1#Russell Ellison Employment Agreement, dated April 17, 2020 (filed with the SEC as Exhibit 10.1 to the Company’s Form 8-K filed on April 20, 2020)
10.2#Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive plan (filed with the SEC as Exhibit 10.1 to the Company’s Form 8-K filed on May 21, 2020)
31.1*
31.1*
31.2*
32.1#*32.1**
101.INS*XBRL Instance Document
101.SCH*XBRL Taxonomy Extension Schema
101.CAL*XBRL Taxonomy Extension Calculation Linkbase
101.DEF*XBRL Taxonomy Extension Definition Database
101.LAB*XBRL Taxonomy Extension Label Linkbase
101.PRE*XBRL Taxonomy Extension Presentation Linkbase
104*The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020,2021, formatted in Inline XBRL (included as Exhibit 101)

*    Filed herewith
#**Filed herewith
**Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.Act

#    Indicates management contracts or compensatory plans or arrangements.

34

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROCKWELL MEDICAL, INC.
(Registrant)
Date: August 16, 2021/s/ Russell Ellison
Russell Ellison
Chief Executive Officer (Principal Executive Officer)
ROCKWELL MEDICAL, INC.
(Registrant)
Date: August 10, 202016, 2021/s/ Russell EllisonSkibsted
Russell Ellison
Skibsted
Chief ExecutiveFinancial Officer (Principal ExecutiveFinancial Officer)
Date: August 10, 2020/s/ Paul E. McGarry
Paul E. McGarry
Controller and Principal Accounting Officer

4335